CREATE TABLE IF NOT EXISTS PREDICATION_OPENIE                  (predication_id INTEGER PRIMARY KEY,                   pmid INTEGER,                   subject_cui VARCHAR,                   subject_name VARCHAR,                   subject_semtype VARCHAR,                   object_cui VARCHAR,                   object_name VARCHAR,                   object_semtype VARCHAR,                   predication VARCHAR,                   sentence VARCHAR );
INSERT INTO PREDICATION_OPENIE VALUES 
(0, 1374415, '2244', 'fibrinogen', 'Gene', '1934', 'beta 3', 'Gene', 'be with', 'Specifically , FG cells expressing beta 3 acquire the capacity to attach and spread on vitronectin as well as fibrinogen with beta 3 localization to focal contacts .'),
(1, 1376732, '3161', 'rhamm', 'Gene', '3161', 'receptor for hyaluronan-mediated motility', 'Gene', 'acronym for', 'It is named RHAMM , an acronym for receptor for hyaluronan-mediated motility .'),
(2, 1374413, '6402', 'l-selectin', 'Gene', 'MESH:D002241', 'carbohydrate', 'Chemical', 'bind to', 'Although L-selectin has been demonstrated to bind to carbohydrates , structural features of potential mammalian carbohydrate ligand -LRB- s -RRB- have not been well defined .'),
(3, 1374413, '6402', 'l-selectin', 'Gene', 'MESH:D002241', 'carbohydrate', 'Chemical', 'bind to', 'Although L-selectin has been demonstrated to bind to carbohydrates , structural features of potential mammalian carbohydrate ligand -LRB- s -RRB- have not been well defined .'),
(4, 1374413, '6402', 'l-selectin', 'Gene', 'MESH:D002241', 'carbohydrate', 'Chemical', 'bind to', 'Although L-selectin has been demonstrated to bind to carbohydrates , structural features of potential mammalian carbohydrate ligand -LRB- s -RRB- have not been well defined .'),
(5, 1374413, '6402', 'l-selectin', 'Gene', 'MESH:D002241', 'carbohydrate', 'Chemical', 'bind to', 'Although L-selectin has been demonstrated to bind to carbohydrates , structural features of potential mammalian carbohydrate ligand -LRB- s -RRB- have not been well defined .'),
(6, 1374413, '6402', 'l-selectin', 'Gene', 'MESH:D002241', 'carbohydrate', 'Chemical', 'bind to', 'Although L-selectin has been demonstrated to bind to carbohydrates , structural features of potential mammalian carbohydrate ligand -LRB- s -RRB- have not been well defined .'),
(7, 1374413, 'MESH:D002241', 'carbohydrate', 'Chemical', 'MESH:D002241', 'carbohydrate', 'Chemical', 'feature of', 'Although L-selectin has been demonstrated to bind to carbohydrates , structural features of potential mammalian carbohydrate ligand -LRB- s -RRB- have not been well defined .'),
(8, 1572895, '12081', 'virus', 'Species', '10116', 'rat', 'Species', 'be in', 'We compared the surface envelope glycoprotein distribution and the budding polarity of four RNA viruses in Fischer rat thyroid -LRB- FRT -RRB- cells and in CaCo-2 cells derived from a human colon carcinoma .'),
(9, 25568625, '9606', 'men', 'Species', '9606', 'men', 'Species', 'be perform on', 'ESWL treatment is performed on the machine Siemens Model Lithostar Multiline , which has a combined ultrasonographic and fluoroscopic display , large energy density in order to obtain optimum focus -LRB- without damaging surrounding tissue -RRB- and minimal pain that on rare occasions requires for mild sedation-sedation .'),
(10, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(11, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(12, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(13, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(14, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(15, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(16, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(17, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(18, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(19, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(20, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(21, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(22, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(23, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(24, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(25, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(26, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(27, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(28, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(29, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(30, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(31, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(32, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(33, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(34, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(35, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(36, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(37, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(38, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(39, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(40, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(41, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(42, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(43, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(44, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(45, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(46, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(47, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(48, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(49, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(50, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(51, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(52, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(53, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(54, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(55, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(56, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(57, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(58, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(59, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(60, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(61, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(62, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(63, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(64, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(65, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(66, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(67, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(68, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(69, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(70, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(71, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(72, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(73, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(74, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(75, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(76, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(77, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(78, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(79, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(80, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(81, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(82, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(83, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(84, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(85, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(86, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(87, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(88, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(89, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(90, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(91, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(92, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(93, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(94, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(95, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(96, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(97, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(98, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(99, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(100, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(101, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(102, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(103, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(104, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(105, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(106, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(107, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(108, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(109, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(110, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(111, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(112, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(113, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(114, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(115, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(116, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(117, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(118, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(119, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(120, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(121, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(122, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(123, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(124, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(125, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(126, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(127, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(128, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(129, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(130, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(131, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(132, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(133, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(134, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(135, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(136, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(137, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(138, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(139, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(140, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(141, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(142, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(143, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(144, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(145, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(146, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(147, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(148, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(149, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(150, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(151, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(152, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(153, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(154, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(155, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(156, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(157, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(158, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(159, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(160, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(161, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(162, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(163, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(164, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(165, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(166, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(167, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(168, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(169, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(170, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(171, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(172, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(173, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(174, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(175, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(176, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(177, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(178, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(179, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(180, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(181, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(182, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(183, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(184, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(185, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(186, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(187, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(188, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(189, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(190, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(191, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(192, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(193, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(194, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(195, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(196, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(197, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(198, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(199, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(200, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(201, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(202, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(203, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(204, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(205, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(206, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(207, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(208, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(209, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(210, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(211, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(212, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(213, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(214, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(215, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(216, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(217, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(218, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(219, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(220, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(221, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(222, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(223, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(224, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(225, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(226, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(227, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(228, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(229, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(230, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(231, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(232, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(233, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(234, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(235, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(236, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(237, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(238, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(239, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(240, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(241, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(242, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(243, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(244, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(245, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(246, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(247, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(248, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(249, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(250, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(251, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(252, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(253, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(254, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(255, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(256, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(257, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(258, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(259, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(260, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(261, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(262, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(263, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(264, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(265, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(266, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(267, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(268, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(269, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(270, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(271, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(272, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(273, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(274, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(275, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(276, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(277, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(278, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(279, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(280, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(281, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(282, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(283, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(284, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(285, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(286, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(287, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(288, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(289, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(290, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(291, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(292, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(293, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(294, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(295, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(296, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(297, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(298, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(299, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(300, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(301, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(302, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(303, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(304, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(305, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(306, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(307, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(308, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(309, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(310, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(311, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(312, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(313, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(314, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(315, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(316, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(317, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(318, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(319, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(320, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(321, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(322, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(323, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(324, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(325, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(326, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(327, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(328, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(329, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(330, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(331, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(332, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(333, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(334, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(335, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(336, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(337, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(338, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(339, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(340, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(341, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(342, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(343, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(344, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(345, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(346, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(347, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(348, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(349, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(350, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(351, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(352, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(353, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(354, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(355, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(356, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(357, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(358, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(359, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(360, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(361, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(362, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(363, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(364, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(365, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(366, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(367, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(368, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(369, 25568637, 'MESH:D009101', 'myeloma', 'Disease', 'MESH:D009101', 'myeloma', 'Disease', 'be', 'Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .'),
(370, 25568637, '9606', 'patient', 'Species', 'MESH:D009101', 'myeloma', 'Disease', 'be with', 'In recent years there is a huge improvement in treatment of patients with multiple myeloma .'),
(371, 25568637, '9606', 'patient', 'Species', 'MESH:D009101', 'myeloma', 'Disease', 'be with', 'So , the major challenge for hematologist is to translate this improvement in the elderly patients with multiple myeloma .'),
(372, 25568637, '9606', 'patient', 'Species', 'MESH:D009101', 'myeloma', 'Disease', 'be with', 'Today , physicians are able to offer wider variety of treatment options for elderly patients with multiple myeloma .'),
(373, 25568637, '9606', 'patient', 'Species', 'MESH:D009101', 'myeloma', 'Disease', 'be with', 'In the mode of sequencing treatment for elderly patients with multiple myeloma , our goal is to achieve and maintain maximal response while limiting treatment - related toxicities as much as possible .'),
(374, 1607381, 'MESH:C020361', 'gamma-adaptin', 'Chemical', 'MESH:D020126', 'bfa', 'Chemical', 'be block by', 'This was confirmed using an in vitro assay in which gamma-adaptin binding to TGN membranes was blocked by BFA and enhanced by GTP gamma S , similar to the binding of beta-COP to Golgi membranes .'),
(375, 1607381, 'MESH:C020361', 'gamma-adaptin', 'Chemical', 'MESH:D016244', 'gtp gamma s', 'Chemical', 'enhance by', 'This was confirmed using an in vitro assay in which gamma-adaptin binding to TGN membranes was blocked by BFA and enhanced by GTP gamma S , similar to the binding of beta-COP to Golgi membranes .'),
(376, 25497602, '9606', 'patient', 'Species', 'MESH:D000544', 'ad', 'Disease', 'be treat in', 'All patients were treated to 35-36.25 Gy in 5 fractions delivered with the CyberKnife Radiosurgical System -LRB- Accuray -RRB- .'),
(377, 25497602, '9606', 'patient', 'Species', 'MESH:D000544', 'ad', 'Disease', 'be', 'All patients were treated to 35-36.25 Gy in 5 fractions delivered with the CyberKnife Radiosurgical System -LRB- Accuray -RRB- .'),
(378, 25497602, 'MESH:D013684', 'telangiectasia', 'Disease', 'MESH:C564884', 'vrs', 'Disease', 'use', 'Telangiectasias were graded using the Vienna Rectoscopy Score -LRB- VRS -RRB- .'),
(379, 25497602, 'MESH:D013684', 'telangiectasia', 'Disease', 'MESH:D000544', 'ad', 'Disease', 'be', 'Telangiectasias were graded using the Vienna Rectoscopy Score -LRB- VRS -RRB- .'),
(380, 25497602, 'MESH:D013684', 'telangiectasia', 'Disease', '9606', 'patient', 'Species', 'be in', 'Endoscopy revealed VRS Grade 2 rectal telangiectasias in 11 % of patients .'),
(381, 1374414, '6714', 'c-src', 'Gene', 'CVCL:0481', 'pc12', 'CellLine', 'of association be', 'Specific association of the proto-oncogene product pp60c-src with an intracellular organelle , the PC12 synaptic vesicle .'),
(382, 1374414, '6714', 'c-src', 'Gene', '6714', 'c-src', 'Gene', 'be associate', 'The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .'),
(383, 1374414, '6714', 'c-src', 'Gene', '6714', 'c-src', 'Gene', 'be associate', 'The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .'),
(384, 1374414, '6714', 'c-src', 'Gene', '6714', 'c-src', 'Gene', 'be specifically associate', 'The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .'),
(385, 1374414, '6714', 'c-src', 'Gene', '6714', 'c-src', 'Gene', 'be associate', 'The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .'),
(386, 1374414, '6714', 'c-src', 'Gene', '6714', 'c-src', 'Gene', 'be specifically associate', 'The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .'),
(387, 1374414, '6714', 'c-src', 'Gene', 'MESH:D016708', 'synaptophysin', 'Chemical', 'overlap with', 'The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .'),
(388, 1374414, '6714', 'c-src', 'Gene', '6714', 'c-src', 'Gene', 'be associate', 'The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .'),
(389, 1374414, '6714', 'c-src', 'Gene', '6714', 'c-src', 'Gene', 'be associate', 'The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .'),
(390, 1374414, '6714', 'c-src', 'Gene', '6714', 'c-src', 'Gene', 'be specifically associate', 'The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .'),
(391, 1374414, '6714', 'c-src', 'Gene', '6714', 'c-src', 'Gene', 'be associate', 'The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .'),
(392, 1374414, '6714', 'c-src', 'Gene', 'MESH:D016708', 'synaptophysin', 'Chemical', 'overlap with', 'The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .'),
(393, 1374414, '6714', 'c-src', 'Gene', '6714', 'c-src', 'Gene', 'be specifically associate', 'The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .'),
(394, 1374414, '6714', 'c-src', 'Gene', '6714', 'c-src', 'Gene', 'be specifically associate', 'The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .'),
(395, 1374414, '6714', 'c-src', 'Gene', '6714', 'c-src', 'Gene', 'be specifically associate', 'The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .'),
(396, 1315787, 'MESH:D007239', 'infection', 'Disease', '12081', 'virus', 'Species', 'be with', 'Double infection of multinucleated L6 muscle cells with Semliki Forest virus and VSV at high multiplicities showed that the glycoprotein of each virus occupied intracellular domains which were devoid of the other respective glycoprotein .'),
(397, 1315314, '4481', 'sr alpha', 'Gene', '4481', 'sr alpha', 'Gene', 'be', 'The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .'),
(398, 1315314, '4481', 'sr alpha', 'Gene', '4481', 'sr alpha', 'Gene', 'be', 'The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .'),
(399, 1315314, '4481', 'sr alpha', 'Gene', '4481', 'sr alpha', 'Gene', 'be', 'The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .'),
(400, 1315314, '4481', 'sr alpha', 'Gene', '4481', 'sr alpha', 'Gene', 'be', 'The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .'),
(401, 1315314, '4481', 'sr alpha', 'Gene', '4481', 'sr alpha', 'Gene', 'be', 'The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .'),
(402, 1315314, '4481', 'sr alpha', 'Gene', '4481', 'sr alpha', 'Gene', 'be repopulate with', 'The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .'),
(403, 1315314, '4481', 'sr alpha', 'Gene', '4481', 'sr alpha', 'Gene', 'be', 'The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .'),
(404, 1315314, '4481', 'sr alpha', 'Gene', '4481', 'sr alpha', 'Gene', 'be', 'The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .'),
(405, 1315314, '4481', 'sr alpha', 'Gene', '4481', 'sr alpha', 'Gene', 'be', 'The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .'),
(406, 1315314, '4481', 'sr alpha', 'Gene', '4481', 'sr alpha', 'Gene', 'be', 'The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .'),
(407, 1315314, '4481', 'sr alpha', 'Gene', '4481', 'sr alpha', 'Gene', 'be', 'The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .'),
(408, 1315314, '4481', 'sr alpha', 'Gene', '4481', 'sr alpha', 'Gene', 'be', 'The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .'),
(409, 1315314, '4481', 'sr alpha', 'Gene', '4481', 'sr alpha', 'Gene', 'be', 'The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .'),
(410, 1315314, '4481', 'sr alpha', 'Gene', '4481', 'sr alpha', 'Gene', 'be', 'The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .'),
(411, 1315314, '6729', 'srp', 'Gene', 'MESH:D000641', 'nh', 'Chemical', 'form', 'These SRP receptors were likewise unable to form Gpp -LRB- NH -RRB- p stabilized complexes with the SRP .'),
(412, 1315314, 'MESH:D006160', 'gtp', 'Chemical', '6729', 'srp', 'Gene', 'be in', 'This mutant has provided information on the reaction step in protein translocation that involves the GTP binding site in the alpha subunit of the SRP receptor .'),
(413, 1560033, 'MESH:D002118', 'calcium', 'Chemical', 'MESH:C031463', 'beta glycerophosphate', 'Chemical', 'occur regardless of', 'Calcium deposition in the extracellular matrix occurred regardless of the addition of beta glycerophosphate to the culture medium .'),
(414, 1560033, 'MESH:D002118', 'calcium', 'Chemical', 'MESH:C031463', 'beta glycerophosphate', 'Chemical', 'occur regardless of', 'Calcium deposition in the extracellular matrix occurred regardless of the addition of beta glycerophosphate to the culture medium .'),
(415, 1560033, 'MESH:D014212', 'retinoic acid', 'Chemical', 'MESH:D006984', 'hypertrophic', 'Disease', 'be', 'When retinoic acid was added to the hypertrophic chondrocyte culture between day 1 and day 5 the maturation of the cells to the osteoblast-like stage was highly accelerated .'),
(416, 1560033, 'MESH:D014212', 'retinoic acid', 'Chemical', 'MESH:D006984', 'hypertrophic', 'Disease', 'be', 'When retinoic acid was added to the hypertrophic chondrocyte culture between day 1 and day 5 the maturation of the cells to the osteoblast-like stage was highly accelerated .'),
(417, 1560033, 'MESH:D014212', 'retinoic acid', 'Chemical', 'MESH:D006984', 'hypertrophic', 'Disease', 'be', 'When retinoic acid was added to the hypertrophic chondrocyte culture between day 1 and day 5 the maturation of the cells to the osteoblast-like stage was highly accelerated .'),
(418, 1560033, 'MESH:D014212', 'retinoic acid', 'Chemical', 'MESH:D006984', 'hypertrophic', 'Disease', 'be add to', 'When retinoic acid was added to the hypertrophic chondrocyte culture between day 1 and day 5 the maturation of the cells to the osteoblast-like stage was highly accelerated .'),
(419, 25511509, '9940', 'sheep', 'Species', 'MESH:D002244', 'c', 'Chemical', 'be', 'Background Sheep are valuable resources for the animal fibre industry .'),
(420, 25511509, '9940', 'sheep', 'Species', 'MESH:D009584', 'n', 'Chemical', 'be resource for', 'Background Sheep are valuable resources for the animal fibre industry .'),
(421, 25511509, '9940', 'sheep', 'Species', 'MESH:D009584', 'n', 'Chemical', 'be valuable resource for', 'Background Sheep are valuable resources for the animal fibre industry .'),
(422, 25511509, '9940', 'sheep', 'Species', 'MESH:D002244', 'c', 'Chemical', 'be', 'Background Sheep are valuable resources for the animal fibre industry .'),
(423, 25511509, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'be verify by means of', 'The microarray results were verified by means of quantitative PCR .'),
(424, 25511509, 'MESH:D002244', 'c', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be verify by means of', 'The microarray results were verified by means of quantitative PCR .'),
(425, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'could distinguish', 'Cluster analysis could distinguish the body side skin and the groin skin .'),
(426, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'could distinguish', 'Cluster analysis could distinguish the body side skin and the groin skin .'),
(427, 25511509, 'MESH:D002244', 'c', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'regulation of', 'Based on the Database for Annotation , Visualization and Integrated Discovery -LRB- DAVID -RRB- , 38 of the differentially expressed genes were classified into four categories , namely regulation of receptor binding , multicellular organismal process , protein binding and macromolecular complex .'),
(428, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'show', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(429, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'difference in', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(430, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'difference in', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(431, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'show', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(432, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'show', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(433, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'show', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(434, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'show', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(435, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'significant difference in', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(436, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'show', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(437, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'show', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(438, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'show', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(439, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'significant difference in', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(440, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'significant difference in', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(441, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'difference in', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(442, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'significant difference in', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(443, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'show', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(444, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'show', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(445, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be in', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(446, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'show', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(447, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'show', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(448, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'difference in', 'Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .'),
(449, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .'),
(450, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .'),
(451, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .'),
(452, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .'),
(453, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .'),
(454, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be identify by', 'Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .'),
(455, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be identify by', 'Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .'),
(456, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be further identify by', 'Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .'),
(457, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .'),
(458, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be further identify by', 'Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .'),
(459, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .'),
(460, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .'),
(461, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'be', 'Conclusions Microarray analysis revealed thousands of differentially expressed genes , many of which were possibly associated with wool growth .'),
(462, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'be', 'Conclusions Microarray analysis revealed thousands of differentially expressed genes , many of which were possibly associated with wool growth .'),
(463, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'might participate in', 'Several potential gene families might participate in hair growth regulation .'),
(464, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'might participate in', 'Several potential gene families might participate in hair growth regulation .'),
(465, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'online version of', 'Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .'),
(466, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'version of', 'Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .'),
(467, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'version of', 'Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .'),
(468, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'contain', 'Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .'),
(469, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'online version of', 'Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .'),
(470, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'online version of', 'Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .'),
(471, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'contain', 'Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .'),
(472, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'version of', 'Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .'),
(473, 25511509, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'contain', 'Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .'),
(474, 1374417, '10116', 'rat', 'Species', 'MESH:D002784', 'cholesterol', 'Chemical', 'be in', 'We have raised two monospecific antibodies against synthetic peptides derived from the membrane domain of the ER glycoprotein 3-hydroxy-3 - methylglutaryl coenzyme A -LRB- HMG-CoA -RRB- reductase , the rate limiting enzyme in the cholesterol biosynthetic pathway .'),
(475, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'be with', 'PKC epsilon-related kinase associates with and phosphorylates cytokeratin 8 and 18 .'),
(476, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'associate with', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(477, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'associate with', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(478, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'be find', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(479, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'associate with', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(480, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'be find', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(481, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'be find', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(482, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'associate with', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(483, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'associate with', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(484, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'associate with', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(485, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'be find', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(486, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'associate with', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(487, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'be find', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(488, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'associate with', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(489, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'be find', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(490, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'be find', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(491, 1374067, '5581', 'pkc epsilon', 'Gene', '10116', 'rat', 'Species', 'be find', 'A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .'),
(492, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(493, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(494, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(495, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(496, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(497, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(498, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(499, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(500, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(501, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(502, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(503, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(504, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(505, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(506, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(507, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(508, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(509, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(510, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(511, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(512, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(513, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(514, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(515, 1374067, '10116', 'rat', 'Species', '3856', 'ck8', 'Gene', 'inhibit', 'A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .'),
(516, 1577863, '871', 'hsp47', 'Gene', '871', 'hsp47', 'Gene', 'be show', 'HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .'),
(517, 1577863, '871', 'hsp47', 'Gene', '871', 'hsp47', 'Gene', 'be show', 'HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .'),
(518, 1577863, '871', 'hsp47', 'Gene', '871', 'hsp47', 'Gene', 'be show', 'HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .'),
(519, 1577863, '871', 'hsp47', 'Gene', '871', 'hsp47', 'Gene', 'be show', 'HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .'),
(520, 1577863, '871', 'hsp47', 'Gene', '871', 'hsp47', 'Gene', 'be show', 'HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .'),
(521, 1577863, '871', 'hsp47', 'Gene', '871', 'hsp47', 'Gene', 'be show', 'HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .'),
(522, 1577863, '871', 'hsp47', 'Gene', '871', 'hsp47', 'Gene', 'be show', 'HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .'),
(523, 1577863, '871', 'hsp47', 'Gene', '871', 'hsp47', 'Gene', 'be show', 'HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .'),
(524, 1577863, '871', 'hsp47', 'Gene', '871', 'hsp47', 'Gene', 'be show', 'HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .'),
(525, 1572893, 'MESH:D009584', 'n', 'Chemical', 'MESH:C040349', 'myristoylcoa', 'Chemical', 'modulate', 'Regulation of myristoylCoA pools in Saccharomyces cerevisiae plays an important role in modulating the activity of myristoylCoA : protein N - myristoyltransferase -LRB- NMT -RRB- , an essential enzyme with an ordered Bi Bi reaction that catalyzes the transfer of myristate from myristoylCoA to greater than or equal to 12 cellular proteins .'),
(526, 1572893, 'MESH:D009584', 'n', 'Chemical', '4932', 'saccharomyces cerevisiae', 'Species', 'be in', 'Regulation of myristoylCoA pools in Saccharomyces cerevisiae plays an important role in modulating the activity of myristoylCoA : protein N - myristoyltransferase -LRB- NMT -RRB- , an essential enzyme with an ordered Bi Bi reaction that catalyzes the transfer of myristate from myristoylCoA to greater than or equal to 12 cellular proteins .'),
(527, 1572893, 'MESH:D009584', 'n', 'Chemical', 'MESH:D001729', 'bi bi', 'Chemical', 'enzyme with', 'Regulation of myristoylCoA pools in Saccharomyces cerevisiae plays an important role in modulating the activity of myristoylCoA : protein N - myristoyltransferase -LRB- NMT -RRB- , an essential enzyme with an ordered Bi Bi reaction that catalyzes the transfer of myristate from myristoylCoA to greater than or equal to 12 cellular proteins .'),
(528, 1572893, 'MESH:D009584', 'n', 'Chemical', 'MESH:D001729', 'bi bi', 'Chemical', 'be with', 'Regulation of myristoylCoA pools in Saccharomyces cerevisiae plays an important role in modulating the activity of myristoylCoA : protein N - myristoyltransferase -LRB- NMT -RRB- , an essential enzyme with an ordered Bi Bi reaction that catalyzes the transfer of myristate from myristoylCoA to greater than or equal to 12 cellular proteins .'),
(529, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'have', 'The FAA1 -LRB- fatty acid activation -RRB- gene has been isolated by genetic complementation of a faal mutant .'),
(530, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'have', 'The FAA1 -LRB- fatty acid activation -RRB- gene has been isolated by genetic complementation of a faal mutant .'),
(531, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'have', 'The FAA1 -LRB- fatty acid activation -RRB- gene has been isolated by genetic complementation of a faal mutant .'),
(532, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'have', 'The FAA1 -LRB- fatty acid activation -RRB- gene has been isolated by genetic complementation of a faal mutant .'),
(533, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'have', 'The FAA1 -LRB- fatty acid activation -RRB- gene has been isolated by genetic complementation of a faal mutant .'),
(534, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'have', 'The FAA1 -LRB- fatty acid activation -RRB- gene has been isolated by genetic complementation of a faal mutant .'),
(535, 1572893, 'MESH:D009584', 'n', 'Chemical', 'MESH:D000214', 'acylcoa', 'Chemical', 'specify', 'This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .'),
(536, 1572893, 'MESH:D009584', 'n', 'Chemical', 'MESH:D000214', 'acylcoa', 'Chemical', 'specify', 'This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .'),
(537, 1572893, 'MESH:D009584', 'n', 'Chemical', 'MESH:D000214', 'acylcoa', 'Chemical', 'specify', 'This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .'),
(538, 1572893, 'MESH:D009584', 'n', 'Chemical', 'MESH:D000214', 'acylcoa', 'Chemical', 'specify', 'This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .'),
(539, 1572893, 'MESH:D009584', 'n', 'Chemical', 'MESH:D000214', 'acylcoa', 'Chemical', 'specify', 'This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .'),
(540, 1572893, 'MESH:D009584', 'n', 'Chemical', 'MESH:D000214', 'acylcoa', 'Chemical', 'specify', 'This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .'),
(541, 1572893, 'MESH:D009584', 'n', 'Chemical', 'MESH:D000214', 'acylcoa', 'Chemical', 'specify', 'This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .'),
(542, 1572893, 'MESH:D009584', 'n', 'Chemical', 'MESH:D000214', 'acylcoa', 'Chemical', 'specify', 'This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .'),
(543, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(544, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(545, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(546, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(547, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(548, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(549, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be require for', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(550, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(551, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(552, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be require for', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(553, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(554, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(555, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(556, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(557, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(558, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be require for', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(559, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(560, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(561, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(562, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be require for', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(563, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(564, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(565, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be require for', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(566, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(567, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(568, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(569, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(570, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(571, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(572, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(573, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(574, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(575, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(576, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(577, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(578, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(579, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(580, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(581, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(582, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(583, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(584, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(585, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(586, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(587, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(588, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(589, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(590, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(591, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(592, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(593, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(594, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(595, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be require for', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(596, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(597, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(598, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(599, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(600, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(601, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(602, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(603, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(604, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(605, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(606, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(607, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(608, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(609, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(610, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(611, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(612, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be require for', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(613, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(614, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(615, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be require for', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(616, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(617, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(618, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(619, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(620, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be require for', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(621, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be require for', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(622, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(623, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be require for', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(624, 1572893, '854495', 'faa1', 'Gene', 'MESH:D009226', 'myristate', 'Chemical', 'be', 'At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .'),
(625, 1315318, '310738', 'beta-nerve growth factor', 'Gene', 'MESH:D013739', 'testosterone', 'Chemical', 'have', 'beta-Nerve growth factor -LRB- NGF -RRB- is expressed in spermatogenic cells and has testosterone-downregulated low-affinity receptors on Sertoli cells suggesting a paracrine role in the regulation of spermatogenesis .'),
(626, 1315318, '310738', 'beta-nerve growth factor', 'Gene', 'MESH:D013739', 'testosterone', 'Chemical', 'have', 'beta-Nerve growth factor -LRB- NGF -RRB- is expressed in spermatogenic cells and has testosterone-downregulated low-affinity receptors on Sertoli cells suggesting a paracrine role in the regulation of spermatogenesis .'),
(627, 1315318, '310738', 'beta-nerve growth factor', 'Gene', 'MESH:D013739', 'testosterone', 'Chemical', 'have', 'beta-Nerve growth factor -LRB- NGF -RRB- is expressed in spermatogenic cells and has testosterone-downregulated low-affinity receptors on Sertoli cells suggesting a paracrine role in the regulation of spermatogenesis .'),
(628, 1315318, '310738', 'ngf', 'Gene', 'MESH:C536875', 'meiosis', 'Disease', 'stimulate dna synthesis with', 'NGF was shown to stimulate in vitro DNA synthesis of seminiferous tubule segments with preleptotene spermatocytes at the onset of meiosis while other segments remained nonresponsive .'),
(629, 1577856, '', 'pmn', 'Disease', 'MESH:C028877', 'nbd-phallicidin', 'Chemical', 'be label with', 'PMN were labeled with fluorescent probe NBD-phallicidin to measure filamentous actin and Texas red to assess cell thickness .'),
(630, 1577856, '', 'pmn', 'Disease', 'MESH:C028877', 'nbd-phallicidin', 'Chemical', 'be label with', 'PMN were labeled with fluorescent probe NBD-phallicidin to measure filamentous actin and Texas red to assess cell thickness .'),
(631, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .'),
(632, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be involve in', 'Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .'),
(633, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .'),
(634, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be involve in', 'Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .'),
(635, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be involve in', 'Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .'),
(636, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be involve in', 'Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .'),
(637, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .'),
(638, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be involve in', 'Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .'),
(639, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be involve in', 'Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .'),
(640, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be involve in', 'Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .'),
(641, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be involve in', 'Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .'),
(642, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .'),
(643, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(644, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(645, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(646, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(647, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(648, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(649, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(650, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(651, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(652, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(653, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(654, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(655, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(656, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(657, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(658, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(659, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(660, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(661, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(662, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(663, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'engage in', 'The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .'),
(664, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be in', 'To investigate the functional properties of the different structural domains of the molecule in cell interactions and signal transduction to the cell interior , we have synthesized , in a bacterial expression system , the individual domains and tandem sets of individual domains as protein fragments .'),
(665, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'promote', 'These protein fragments were tested for their capacity to influence adhesion and spreading of neuronal cell bodies , promote neurite outgrowth , and influence cellular migration patterns from cerebellar microexplants in vitro .'),
(666, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be increase by', 'Outgrowth of astrocytic processes from the explant core was influenced only by Ig - like domain I. Metabolism of inositol phosphates was strongly increased by Ig-like domain I and less by the Ig-like domains II , III , IV , and V , and not influenced by the combined type III repeats I-II .'),
(667, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Outgrowth of astrocytic processes from the explant core was influenced only by Ig - like domain I. Metabolism of inositol phosphates was strongly increased by Ig-like domain I and less by the Ig-like domains II , III , IV , and V , and not influenced by the combined type III repeats I-II .'),
(668, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Outgrowth of astrocytic processes from the explant core was influenced only by Ig - like domain I. Metabolism of inositol phosphates was strongly increased by Ig-like domain I and less by the Ig-like domains II , III , IV , and V , and not influenced by the combined type III repeats I-II .'),
(669, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be increase by', 'Outgrowth of astrocytic processes from the explant core was influenced only by Ig - like domain I. Metabolism of inositol phosphates was strongly increased by Ig-like domain I and less by the Ig-like domains II , III , IV , and V , and not influenced by the combined type III repeats I-II .'),
(670, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be increase by', 'Outgrowth of astrocytic processes from the explant core was influenced only by Ig - like domain I. Metabolism of inositol phosphates was strongly increased by Ig-like domain I and less by the Ig-like domains II , III , IV , and V , and not influenced by the combined type III repeats I-II .'),
(671, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Outgrowth of astrocytic processes from the explant core was influenced only by Ig - like domain I. Metabolism of inositol phosphates was strongly increased by Ig-like domain I and less by the Ig-like domains II , III , IV , and V , and not influenced by the combined type III repeats I-II .'),
(672, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be increase by', 'Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .'),
(673, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .'),
(674, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be increase by', 'Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .'),
(675, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .'),
(676, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be increase by', 'Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .'),
(677, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be increase by', 'Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .'),
(678, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be increase by', 'Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .'),
(679, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be increase by', 'Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .'),
(680, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be increase by', 'Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .'),
(681, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be increase by', 'Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .'),
(682, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'different', 'These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .'),
(683, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be in', 'These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .'),
(684, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'domain of', 'These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .'),
(685, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'different', 'These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .'),
(686, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'different', 'These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .'),
(687, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'different', 'These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .'),
(688, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'different', 'These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .'),
(689, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'different domain of', 'These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .'),
(690, 1618903, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'different', 'These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .'),
(691, 1607392, 'MESH:D013431', 'sulfate', 'Chemical', 'MESH:D006493', 'heparin', 'Chemical', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(692, 1607392, 'MESH:D010716', 'phosphatidylinositol', 'Chemical', 'MESH:D008545', 'melanoma', 'Disease', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(693, 1607392, 'MESH:D010716', 'phosphatidylinositol', 'Chemical', 'MESH:D008545', 'melanoma', 'Disease', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(694, 1607392, 'MESH:D010716', 'phosphatidylinositol', 'Chemical', 'MESH:D006493', 'heparin', 'Chemical', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(695, 1607392, 'MESH:D010716', 'phosphatidylinositol', 'Chemical', 'MESH:D006493', 'heparin', 'Chemical', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(696, 1607392, 'MESH:D013431', 'sulfate', 'Chemical', 'MESH:D008545', 'melanoma', 'Disease', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(697, 1607392, 'MESH:D013431', 'sulfate', 'Chemical', 'MESH:D006493', 'heparin', 'Chemical', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(698, 1607392, 'MESH:D013431', 'sulfate', 'Chemical', 'MESH:D008545', 'melanoma', 'Disease', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(699, 1607392, 'MESH:D010716', 'phosphatidylinositol', 'Chemical', 'MESH:D008545', 'melanoma', 'Disease', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(700, 1607392, 'MESH:D010716', 'phosphatidylinositol', 'Chemical', 'MESH:D008545', 'melanoma', 'Disease', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(701, 1607392, 'MESH:D010716', 'phosphatidylinositol', 'Chemical', 'MESH:D006493', 'heparin', 'Chemical', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(702, 1607392, 'MESH:D013431', 'sulfate', 'Chemical', 'MESH:D008545', 'melanoma', 'Disease', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(703, 1607392, 'MESH:D013431', 'sulfate', 'Chemical', 'MESH:D008545', 'melanoma', 'Disease', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(704, 1607392, 'MESH:D010716', 'phosphatidylinositol', 'Chemical', 'MESH:D008545', 'melanoma', 'Disease', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(705, 1607392, 'MESH:D013431', 'sulfate', 'Chemical', 'MESH:D006493', 'heparin', 'Chemical', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(706, 1607392, 'MESH:D010716', 'phosphatidylinositol', 'Chemical', 'MESH:D006493', 'heparin', 'Chemical', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(707, 1607392, 'MESH:D013431', 'sulfate', 'Chemical', 'MESH:D006493', 'heparin', 'Chemical', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(708, 1607392, 'MESH:D013431', 'sulfate', 'Chemical', 'MESH:D008545', 'melanoma', 'Disease', 'initiate', 'Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .'),
(709, 1607392, 'MESH:D006859', 'h ii', 'Chemical', '14268', 'fibronectin', 'Gene', 'peptide from', 'Cell surface heparan sulfate proteoglycan -LRB- HSPG -RRB- from metastatic mouse melanoma cells initiates cell adhesion to the synthetic peptide FN-C/H II , a heparin-binding peptide from the 33-kD A chain-derived fragment of fibronectin .'),
(710, 1607392, 'MESH:D013431', 'sulfate', 'Chemical', 'MESH:D006859', 'h ii', 'Chemical', 'initiate', 'Cell surface heparan sulfate proteoglycan -LRB- HSPG -RRB- from metastatic mouse melanoma cells initiates cell adhesion to the synthetic peptide FN-C/H II , a heparin-binding peptide from the 33-kD A chain-derived fragment of fibronectin .'),
(711, 1607392, 'MESH:D008545', 'melanoma', 'Disease', '15529', 'hspg', 'Gene', 'from proteoglycan be', 'Cell surface heparan sulfate proteoglycan -LRB- HSPG -RRB- from metastatic mouse melanoma cells initiates cell adhesion to the synthetic peptide FN-C/H II , a heparin-binding peptide from the 33-kD A chain-derived fragment of fibronectin .'),
(712, 1607392, 'MESH:D013431', 'sulfate', 'Chemical', 'MESH:D006859', 'h ii', 'Chemical', 'initiate', 'Cell surface heparan sulfate proteoglycan -LRB- HSPG -RRB- from metastatic mouse melanoma cells initiates cell adhesion to the synthetic peptide FN-C/H II , a heparin-binding peptide from the 33-kD A chain-derived fragment of fibronectin .'),
(713, 1607392, 'MESH:D008545', 'melanoma', 'Disease', 'MESH:D006493', 'heparin', 'Chemical', 'be sensitive to', 'Mouse melanoma cell adhesion to FN-C/H II was sensitive to soluble heparin and pretreatment of mouse melanoma cells with heparitinase .'),
(714, 1607392, 'MESH:D008545', 'melanoma', 'Disease', 'MESH:D006493', 'heparin', 'Chemical', 'be sensitive to', 'Mouse melanoma cell adhesion to FN-C/H II was sensitive to soluble heparin and pretreatment of mouse melanoma cells with heparitinase .'),
(715, 1607392, 'MESH:D008545', 'melanoma', 'Disease', 'MESH:D013431', 'sulfate', 'Chemical', 'be label with', 'Mouse melanoma cell HSPG was metabolically labeled with -LSB- 35S -RSB- sulfate and extracted with detergent .'),
(716, 1607392, 'MESH:D008545', 'melanoma', 'Disease', 'MESH:D013431', 'sulfate', 'Chemical', 'be metabolically label with', 'Mouse melanoma cell HSPG was metabolically labeled with -LSB- 35S -RSB- sulfate and extracted with detergent .'),
(717, 1607392, '15529', 'hspg', 'Gene', 'MESH:D008545', 'melanoma', 'Disease', 'purify from', 'Polyclonal antibodies generated against HSPG purified from mouse melanoma cells grown in vivo also identified a 63-kD core protein .'),
(718, 1607392, '15529', 'hspg', 'Gene', 'MESH:D008545', 'melanoma', 'Disease', 'purify from', 'Polyclonal antibodies generated against HSPG purified from mouse melanoma cells grown in vivo also identified a 63-kD core protein .'),
(719, 1607392, '15529', 'hspg', 'Gene', 'MESH:D008545', 'melanoma', 'Disease', 'purify from', 'Polyclonal antibodies generated against HSPG purified from mouse melanoma cells grown in vivo also identified a 63-kD core protein .'),
(720, 1607392, '15529', 'hspg', 'Gene', 'MESH:C059676', 'octyl', 'Chemical', 'be', 'This HSPG is an integral plasma membrane component by virtue of its binding to Octyl Sepharose affinity columns and that anti-HSPG antibody staining exhibited a cell surface localization .'),
(721, 1607392, '15529', 'hspg', 'Gene', 'MESH:C059676', 'octyl', 'Chemical', 'be', 'This HSPG is an integral plasma membrane component by virtue of its binding to Octyl Sepharose affinity columns and that anti-HSPG antibody staining exhibited a cell surface localization .'),
(722, 1607392, '15529', 'hspg', 'Gene', 'MESH:D010716', 'phosphatidylinositol', 'Chemical', 'be anchor through', 'The HSPG is anchored to the cell surface through phosphatidylinositol -LRB- PI -RRB- linkages , as evidenced in part by the ability of PI-specific phospholipase C to eliminate binding of the detergent-extracted HSPG to Octyl Sepharose .'),
(723, 1607392, '15529', 'hspg', 'Gene', 'MESH:D010716', 'phosphatidylinositol', 'Chemical', 'be', 'The HSPG is anchored to the cell surface through phosphatidylinositol -LRB- PI -RRB- linkages , as evidenced in part by the ability of PI-specific phospholipase C to eliminate binding of the detergent-extracted HSPG to Octyl Sepharose .'),
(724, 1607392, 'MESH:D008545', 'melanoma', 'Disease', 'MESH:D004983', '3h-ethanolamine', 'Chemical', 'could', 'Furthermore , the mouse melanoma HSPG core protein could be metabolically labeled with 3H-ethanolamine .'),
(725, 1607392, 'MESH:D008545', 'melanoma', 'Disease', 'MESH:D004983', '3h-ethanolamine', 'Chemical', 'could', 'Furthermore , the mouse melanoma HSPG core protein could be metabolically labeled with 3H-ethanolamine .'),
(726, 1607392, 'MESH:D008545', 'melanoma', 'Disease', 'MESH:D004983', '3h-ethanolamine', 'Chemical', 'could', 'Furthermore , the mouse melanoma HSPG core protein could be metabolically labeled with 3H-ethanolamine .'),
(727, 1607392, 'MESH:D008545', 'melanoma', 'Disease', 'MESH:D004983', '3h-ethanolamine', 'Chemical', 'could', 'Furthermore , the mouse melanoma HSPG core protein could be metabolically labeled with 3H-ethanolamine .'),
(728, 1607392, 'MESH:C492712', '125i', 'Chemical', 'MESH:D006859', 'h ii', 'Chemical', 'bind', 'However , heparitinase-treated 125I-labeled HSPG failed to bind FN-C/H II , suggesting that HS , and not HSPG core protein , binds FN-C/H II .'),
(729, 1607392, 'MESH:C492712', '125i', 'Chemical', 'MESH:D006859', 'h ii', 'Chemical', 'bind', 'However , heparitinase-treated 125I-labeled HSPG failed to bind FN-C/H II , suggesting that HS , and not HSPG core protein , binds FN-C/H II .'),
(730, 1607392, '15529', 'hspg', 'Gene', 'MESH:D006859', 'h ii', 'Chemical', 'bind', 'However , heparitinase-treated 125I-labeled HSPG failed to bind FN-C/H II , suggesting that HS , and not HSPG core protein , binds FN-C/H II .'),
(731, 1607392, '15529', 'hspg', 'Gene', 'MESH:D006859', 'h ii', 'Chemical', 'bind', 'However , heparitinase-treated 125I-labeled HSPG failed to bind FN-C/H II , suggesting that HS , and not HSPG core protein , binds FN-C/H II .'),
(732, 1607392, 'MESH:D010716', 'phosphatidylinositol', 'Chemical', 'MESH:D006859', 'h ii', 'Chemical', 'initiate', 'These data support the hypothesis that a phosphatidylinositol-anchored HSPG on mouse melanoma cells -LRB- MPIHP-63 -RRB- initiates recognition to FN-C/H II , and implicate PI-associated signal transduction pathways in mediating melanoma cell adhesion to this defined ligand .'),
(733, 1607392, '15529', 'hspg', 'Gene', 'MESH:D006859', 'h ii', 'Chemical', 'initiate', 'These data support the hypothesis that a phosphatidylinositol-anchored HSPG on mouse melanoma cells -LRB- MPIHP-63 -RRB- initiates recognition to FN-C/H II , and implicate PI-associated signal transduction pathways in mediating melanoma cell adhesion to this defined ligand .'),
(734, 1315784, '4932', 'yeast', 'Species', '9031', 'chicken', 'Species', 'be', 'Like chicken capping protein , yeast capping protein is inhibited by PIP2 .'),
(735, 1315784, '4932', 'yeast', 'Species', '9031', 'chicken', 'Species', 'be', 'Like chicken capping protein , yeast capping protein is inhibited by PIP2 .'),
(736, 1315784, '4932', 'yeast', 'Species', '9031', 'chicken', 'Species', 'be inhibit like', 'Like chicken capping protein , yeast capping protein is inhibited by PIP2 .'),
(737, 1315784, '4932', 'yeast', 'Species', '9031', 'chicken', 'Species', 'be inhibit like', 'Like chicken capping protein , yeast capping protein is inhibited by PIP2 .'),
(738, 1315784, '4932', 'yeast', 'Species', '854545', 'pip2', 'Gene', 'be inhibit by', 'Like chicken capping protein , yeast capping protein is inhibited by PIP2 .'),
(739, 1315782, 'MESH:C056920', 'f3', 'Chemical', 'CVCL:0213', 'cho', 'CellLine', 'be', 'The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .'),
(740, 1315782, 'MESH:C056920', 'f3', 'Chemical', 'MESH:D010716', 'glycane-phosphatidylinositol', 'Chemical', 'anchor by', 'The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .'),
(741, 1315782, 'MESH:C056920', 'f3', 'Chemical', 'CVCL:0213', 'cho', 'CellLine', 'be', 'The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .'),
(742, 1315782, 'MESH:C056920', 'f3', 'Chemical', 'CVCL:0213', 'cho', 'CellLine', 'be', 'The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .'),
(743, 1315782, 'MESH:C056920', 'f3', 'Chemical', 'CVCL:0213', 'cho', 'CellLine', 'be', 'The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .'),
(744, 1315782, 'MESH:C056920', 'f3', 'Chemical', 'CVCL:0213', 'cho', 'CellLine', 'be', 'The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .'),
(745, 1315782, 'MESH:C056920', 'f3', 'Chemical', 'CVCL:0213', 'cho', 'CellLine', 'be', 'The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .'),
(746, 1315782, 'MESH:C056920', 'f3', 'Chemical', 'CVCL:0213', 'cho', 'CellLine', 'be', 'The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .'),
(747, 1315782, 'MESH:C056920', 'f3', 'Chemical', 'CVCL:0213', 'cho', 'CellLine', 'be', 'The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .'),
(748, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D003967', 'diarrhea', 'Disease', 'be in', 'The massive secretion of salt and water in cholera-induced diarrhea involves binding of cholera toxin -LRB- CT -RRB- to ganglioside GM1 in the apical membrane of intestinal epithelial cells , translocation of the enzymatically active A1-peptide across the membrane , and subsequent activation of adenylate cyclase located on the cytoplasmic surface of the basolateral membrane .'),
(749, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(750, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be strongly inhibit than', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(751, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be more strongly inhibit than', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(752, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(753, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be inhibit at', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(754, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be strongly inhibit than', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(755, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(756, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(757, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be strongly inhibit at', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(758, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be more strongly inhibit than', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(759, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be more strongly inhibit than', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(760, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(761, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(762, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(763, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(764, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be strongly inhibit than', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(765, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(766, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be inhibit than', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(767, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(768, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be more strongly inhibit at', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(769, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be inhibit than', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(770, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be inhibit than', 'At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .'),
(771, 1318883, 'MESH:C027024', 'rhodamine', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'apply at', 'A functional rhodamine-labeled CT-analogue applied apically or basolaterally at 20 degrees C was visualized only within endocytic vesicles close to apical or basolateral membranes , whereas movement into deeper apical structures was detected at 37 degrees C .'),
(772, 1318883, 'MESH:C027024', 'rhodamine', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'apply apically or basolaterally at', 'A functional rhodamine-labeled CT-analogue applied apically or basolaterally at 20 degrees C was visualized only within endocytic vesicles close to apical or basolateral membranes , whereas movement into deeper apical structures was detected at 37 degrees C .'),
(773, 1318883, 'MESH:C027024', 'rhodamine', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'apply at', 'A functional rhodamine-labeled CT-analogue applied apically or basolaterally at 20 degrees C was visualized only within endocytic vesicles close to apical or basolateral membranes , whereas movement into deeper apical structures was detected at 37 degrees C .'),
(774, 1318883, 'MESH:C027024', 'rhodamine', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'apply apically at', 'A functional rhodamine-labeled CT-analogue applied apically or basolaterally at 20 degrees C was visualized only within endocytic vesicles close to apical or basolateral membranes , whereas movement into deeper apical structures was detected at 37 degrees C .'),
(775, 1318883, 'MESH:C027024', 'rhodamine', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'apply apically at', 'A functional rhodamine-labeled CT-analogue applied apically or basolaterally at 20 degrees C was visualized only within endocytic vesicles close to apical or basolateral membranes , whereas movement into deeper apical structures was detected at 37 degrees C .'),
(776, 1318883, 'MESH:C027024', 'rhodamine', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'apply apically or basolaterally at', 'A functional rhodamine-labeled CT-analogue applied apically or basolaterally at 20 degrees C was visualized only within endocytic vesicles close to apical or basolateral membranes , whereas movement into deeper apical structures was detected at 37 degrees C .'),
(777, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be', 'At 15 degrees C , in contrast , reduction to the A1-peptide was completely inhibited and both apical and basolateral CT failed to stimulate Isc although Isc responses to 1 nM vasoactive intestinal peptide , 10 microM forskolin , and 3 mM 8Br - cAMP were intact .'),
(778, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be completely inhibit at', 'At 15 degrees C , in contrast , reduction to the A1-peptide was completely inhibited and both apical and basolateral CT failed to stimulate Isc although Isc responses to 1 nM vasoactive intestinal peptide , 10 microM forskolin , and 3 mM 8Br - cAMP were intact .'),
(779, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be inhibit at', 'At 15 degrees C , in contrast , reduction to the A1-peptide was completely inhibited and both apical and basolateral CT failed to stimulate Isc although Isc responses to 1 nM vasoactive intestinal peptide , 10 microM forskolin , and 3 mM 8Br - cAMP were intact .'),
(780, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be', 'At 15 degrees C , in contrast , reduction to the A1-peptide was completely inhibited and both apical and basolateral CT failed to stimulate Isc although Isc responses to 1 nM vasoactive intestinal peptide , 10 microM forskolin , and 3 mM 8Br - cAMP were intact .'),
(781, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'identify', 'These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .'),
(782, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'identify', 'These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .'),
(783, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'identify', 'These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .'),
(784, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'identify', 'These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .'),
(785, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'identify', 'These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .'),
(786, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'identify', 'These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .'),
(787, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'identify', 'These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .'),
(788, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'identify', 'These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .'),
(789, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'identify', 'These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .'),
(790, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'identify', 'These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .'),
(791, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'identify', 'These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .'),
(792, 1318883, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'identify', 'These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .'),
(793, 25568634, 'MESH:D003967', 'diarrhea', 'Disease', '9606', 'child', 'Species', 'be cause worldwide of', 'Background : Diarrhea is a leading cause of child mortality worldwide .'),
(794, 25568634, 'MESH:D003967', 'diarrhea', 'Disease', '9606', 'child', 'Species', 'be lead cause of', 'Background : Diarrhea is a leading cause of child mortality worldwide .'),
(795, 25568634, 'MESH:D003967', 'diarrhea', 'Disease', '9606', 'child', 'Species', 'be cause of', 'Background : Diarrhea is a leading cause of child mortality worldwide .'),
(796, 25568634, 'MESH:D003967', 'diarrhea', 'Disease', '9606', 'child', 'Species', 'be lead cause worldwide of', 'Background : Diarrhea is a leading cause of child mortality worldwide .'),
(797, 25568634, 'MESH:D003967', 'diarrhea', 'Disease', '9606', 'child', 'Species', 'be in', 'Rotavirus is one of the most common causes of severe diarrhea and dehydration in children .'),
(798, 25568634, '9606', 'child', 'Species', 'MESH:D012400', 'rotavirus diarrhea', 'Disease', 'be with', 'Results : 116 children with rotavirus diarrhea are included in the study .'),
(799, 25568634, 'MESH:D005334', 'fever', 'Disease', 'MESH:D003967', 'diarrhea', 'Disease', 'be characteristic of', 'Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .'),
(800, 25568634, 'MESH:D005334', 'fever', 'Disease', '9606', 'patient', 'Species', 'be', 'Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .'),
(801, 25568634, 'MESH:D005334', 'fever', 'Disease', 'MESH:D003967', 'diarrhea', 'Disease', 'be characteristic of', 'Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .'),
(802, 25568634, 'MESH:D005334', 'fever', 'Disease', '9606', 'patient', 'Species', 'be', 'Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .'),
(803, 25568634, 'MESH:D005334', 'fever', 'Disease', 'MESH:D003967', 'diarrhea', 'Disease', 'be', 'Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .'),
(804, 25568634, 'MESH:D005334', 'fever', 'Disease', '9606', 'patient', 'Species', 'be', 'Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .'),
(805, 25568634, 'MESH:D005334', 'fever', 'Disease', 'MESH:D003967', 'diarrhea', 'Disease', 'be', 'Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .'),
(806, 25568634, 'MESH:D005334', 'fever', 'Disease', 'MESH:D003967', 'diarrhea', 'Disease', 'be characteristic apart from', 'Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .'),
(807, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'be prepare from', 'Membrane-cytoskeletons were prepared from Dictyostelium amebas , and networks of actin and myosin II filaments were visualized on the exposed cytoplasmic surfaces of the cell membranes by fluorescence staining -LRB- Yumura , S. , and T. Kitanishi-Yumura .'),
(808, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D015636', 'mgcl2', 'Chemical', 'remain in', 'By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .'),
(809, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D015636', 'mgcl2', 'Chemical', 'remain in', 'By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .'),
(810, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'remain by', 'By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .'),
(811, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D015636', 'mgcl2', 'Chemical', 'remain in', 'By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .'),
(812, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D015636', 'mgcl2', 'Chemical', 'remain in', 'By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .'),
(813, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'remain in', 'By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .'),
(814, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'remain in', 'By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .'),
(815, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'remain by', 'By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .'),
(816, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'result in', 'Using -LSB- gamma 32P -RSB- ATP , we found that the heavy chains of myosin II released from membrane-cytoskeletons were phosphorylated , and this phosphorylation resulted in disassembly of myosin filaments .'),
(817, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'result in', 'Using -LSB- gamma 32P -RSB- ATP , we found that the heavy chains of myosin II released from membrane-cytoskeletons were phosphorylated , and this phosphorylation resulted in disassembly of myosin filaments .'),
(818, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'occur at', 'Using ITP -LRB- a substrate for myosin II ATPase -RRB- and/or ATP gamma S -LRB- a substrate for myosin II heavy-chain kinase -LSB- MHCK -RSB- -RRB- , we demonstrated that phosphorylation of myosin heavy chains occurred at the foci within the actin network , a result that suggests that MHCK was localized at the foci .'),
(819, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'occur at', 'Using ITP -LRB- a substrate for myosin II ATPase -RRB- and/or ATP gamma S -LRB- a substrate for myosin II heavy-chain kinase -LSB- MHCK -RSB- -RRB- , we demonstrated that phosphorylation of myosin heavy chains occurred at the foci within the actin network , a result that suggests that MHCK was localized at the foci .'),
(820, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'occur', 'Using ITP -LRB- a substrate for myosin II ATPase -RRB- and/or ATP gamma S -LRB- a substrate for myosin II heavy-chain kinase -LSB- MHCK -RSB- -RRB- , we demonstrated that phosphorylation of myosin heavy chains occurred at the foci within the actin network , a result that suggests that MHCK was localized at the foci .'),
(821, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'could represent', 'This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .'),
(822, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'could represent', 'This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .'),
(823, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'could represent', 'This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .'),
(824, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'could represent', 'This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .'),
(825, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'could represent', 'This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .'),
(826, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'could represent', 'This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .'),
(827, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'could represent', 'This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .'),
(828, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'could represent', 'This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .'),
(829, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'could represent', 'This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .'),
(830, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'could represent', 'This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .'),
(831, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'could represent', 'This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .'),
(832, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'could represent', 'This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .'),
(833, 1607385, 'MESH:D013455', 's', 'Chemical', 'MESH:D013455', 's', 'Chemical', 'could represent', 'This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .'),
(834, 1577853, '6517', 'glut-4', 'Gene', 'MESH:D005947', 'glucose', 'Chemical', 'be', 'GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .'),
(835, 1577853, '6517', 'glut-4', 'Gene', 'MESH:D005947', 'glucose', 'Chemical', 'be', 'GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .'),
(836, 1577853, '6517', 'glut-4', 'Gene', 'MESH:D005947', 'glucose', 'Chemical', 'be', 'GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .'),
(837, 1577853, '6517', 'glut-4', 'Gene', 'MESH:D005947', 'glucose', 'Chemical', 'be', 'GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .'),
(838, 1577853, '6517', 'glut-4', 'Gene', 'MESH:D005947', 'glucose', 'Chemical', 'be', 'GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .'),
(839, 1577853, '6517', 'glut-4', 'Gene', 'MESH:D005947', 'glucose', 'Chemical', 'be', 'GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .'),
(840, 1577853, '6517', 'glut-4', 'Gene', 'MESH:D005947', 'glucose', 'Chemical', 'be', 'GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .'),
(841, 1577853, '6517', 'glut-4', 'Gene', 'MESH:D005947', 'glucose', 'Chemical', 'be', 'GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .'),
(842, 1577853, '3630', 'insulin', 'Gene', '6517', 'glut-4', 'Gene', 'regulate glucose transport by', 'Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .'),
(843, 1577853, '3630', 'insulin', 'Gene', '6517', 'glut-4', 'Gene', 'regulate glucose transport by', 'Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .'),
(844, 1577853, '3630', 'insulin', 'Gene', '6517', 'glut-4', 'Gene', 'regulate glucose transport by', 'Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .'),
(845, 1577853, '3630', 'insulin', 'Gene', '6517', 'glut-4', 'Gene', 'regulate glucose transport by', 'Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .'),
(846, 1577853, '3630', 'insulin', 'Gene', '6517', 'glut-4', 'Gene', 'regulate glucose transport by', 'Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .'),
(847, 1577853, '3630', 'insulin', 'Gene', '6517', 'glut-4', 'Gene', 'regulate glucose transport by', 'Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .'),
(848, 1577853, '3630', 'insulin', 'Gene', '6517', 'glut-4', 'Gene', 'regulate glucose transport by', 'Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .'),
(849, 1577853, '3630', 'insulin', 'Gene', '6517', 'glut-4', 'Gene', 'regulate glucose transport by', 'Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .'),
(850, 1577853, '3630', 'insulin', 'Gene', '6517', 'glut-4', 'Gene', 'regulate glucose transport by', 'Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .'),
(851, 1577853, '3630', 'insulin', 'Gene', '6517', 'glut-4', 'Gene', 'regulate glucose transport by', 'Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .'),
(852, 1577853, '3630', 'insulin', 'Gene', '6517', 'glut-4', 'Gene', 'regulate glucose transport by', 'Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .'),
(853, 1577853, '3630', 'insulin', 'Gene', '6517', 'glut-4', 'Gene', 'regulate glucose transport by', 'Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .'),
(854, 1577853, '3630', 'insulin', 'Gene', 'MESH:D005947', 'glucose', 'Chemical', 'regulate', 'Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .'),
(855, 1577853, '6517', 'glut-4', 'Gene', 'CVCL:0213', 'cho', 'CellLine', 'be target to', 'We have found that wild-type GLUT-4 is targeted to an intracellular compartment in CHO cells which is morphologically similar to that observed in adipocytes and muscle cells .'),
(856, 1577853, '6517', 'glut-4', 'Gene', 'CVCL:0213', 'cho', 'CellLine', 'be target to', 'We have found that wild-type GLUT-4 is targeted to an intracellular compartment in CHO cells which is morphologically similar to that observed in adipocytes and muscle cells .'),
(857, 1577853, '6517', 'glut-4', 'Gene', 'CVCL:0213', 'cho', 'CellLine', 'be target to', 'We have found that wild-type GLUT-4 is targeted to an intracellular compartment in CHO cells which is morphologically similar to that observed in adipocytes and muscle cells .'),
(858, 1577853, '6517', 'glut-4', 'Gene', 'CVCL:0213', 'cho', 'CellLine', 'be target to', 'We have found that wild-type GLUT-4 is targeted to an intracellular compartment in CHO cells which is morphologically similar to that observed in adipocytes and muscle cells .'),
(859, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'abrogate', 'Potentiator Ivacaftor Abrogates Pharmacological Correction of DeltaF508 CFTR in Cystic Fibrosis .'),
(860, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cystic fibrosis', 'Disease', 'abrogate correction in', 'Potentiator Ivacaftor Abrogates Pharmacological Correction of DeltaF508 CFTR in Cystic Fibrosis .'),
(861, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'abrogate', 'Potentiator Ivacaftor Abrogates Pharmacological Correction of DeltaF508 CFTR in Cystic Fibrosis .'),
(862, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'abrogate', 'Potentiator Ivacaftor Abrogates Pharmacological Correction of DeltaF508 CFTR in Cystic Fibrosis .'),
(863, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D005355', 'fibrosis', 'Disease', 'abrogate correction in', 'Potentiator Ivacaftor Abrogates Pharmacological Correction of DeltaF508 CFTR in Cystic Fibrosis .'),
(864, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'abrogate', 'Potentiator Ivacaftor Abrogates Pharmacological Correction of DeltaF508 CFTR in Cystic Fibrosis .'),
(865, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'be in', 'Cystic Fibrosis -LRB- CF -RRB- is caused by mutations in the CF transmembrane conductance regulator -LRB- CFTR -RRB- .'),
(866, 25101886, 'MESH:D005355', 'fibrosis', 'Disease', 'MESH:D003550', 'cf', 'Disease', 'be cause by', 'Cystic Fibrosis -LRB- CF -RRB- is caused by mutations in the CF transmembrane conductance regulator -LRB- CFTR -RRB- .'),
(867, 25101886, 'MESH:D005355', 'fibrosis', 'Disease', 'MESH:D009584', 'n', 'Chemical', 'be cause by', 'Cystic Fibrosis -LRB- CF -RRB- is caused by mutations in the CF transmembrane conductance regulator -LRB- CFTR -RRB- .'),
(868, 25101886, 'MESH:D003550', 'cystic fibrosis', 'Disease', 'MESH:D009584', 'n', 'Chemical', 'be cause by', 'Cystic Fibrosis -LRB- CF -RRB- is caused by mutations in the CF transmembrane conductance regulator -LRB- CFTR -RRB- .'),
(869, 25101886, 'MESH:D003550', 'cystic fibrosis', 'Disease', 'MESH:D003550', 'cf', 'Disease', 'be cause by', 'Cystic Fibrosis -LRB- CF -RRB- is caused by mutations in the CF transmembrane conductance regulator -LRB- CFTR -RRB- .'),
(870, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'be in', 'Newly developed `` correctors '''' such as lumacaftor -LRB- VX-809 -RRB- that improve CFTR maturation and trafficking and `` potentiators '''' such as ivacaftor -LRB- VX-770 -RRB- that enhance channel activity may provide important advances in CF therapy .'),
(871, 25101886, '9606', 'patient', 'Species', 'p.508delF', 'deltaf508', 'DNAMutation', 'be with', 'Thus , patients with DeltaF508 will likely require treatment with both correctors and potentiators to achieve clinical benefit .'),
(872, 25101886, 'MESH:D009584', 'n', 'Chemical', 'p.G551D;RS#:75527207', 'g551d', 'ProteinMutation', 'improve cftr function with', 'In studies of human primary airway epithelial cells , we found that both acute and chronic treatment with VX-770 improved CFTR function in cells with the G551D mutation , consistent with clinical studies .'),
(873, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'improve', 'In studies of human primary airway epithelial cells , we found that both acute and chronic treatment with VX-770 improved CFTR function in cells with the G551D mutation , consistent with clinical studies .'),
(874, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'improve', 'In studies of human primary airway epithelial cells , we found that both acute and chronic treatment with VX-770 improved CFTR function in cells with the G551D mutation , consistent with clinical studies .'),
(875, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(876, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(877, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(878, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(879, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(880, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(881, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(882, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(883, 25101886, 'MESH:D009584', 'n', 'Chemical', 'p.508delF', 'deltaf508', 'DNAMutation', 'be in', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(884, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'cause reversal in', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(885, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(886, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(887, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(888, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(889, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(890, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(891, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(892, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(893, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(894, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'cause reversal in', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(895, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(896, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(897, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(898, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(899, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(900, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(901, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(902, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(903, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(904, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(905, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(906, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(907, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(908, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(909, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(910, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(911, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'cause', 'In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .'),
(912, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(913, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(914, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'also reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(915, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(916, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'also reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(917, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'also reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(918, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(919, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(920, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'also reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(921, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'also reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(922, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(923, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'also reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(924, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(925, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(926, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(927, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'also reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(928, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(929, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'also reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(930, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'also reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(931, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'also reduce', 'Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .'),
(932, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D003550', 'cf', 'Disease', 'be with', 'These findings demonstrate that chronic treatment with CFTR potentiators and correctors may have unexpected effects that can not be predicted from short-term studies .'),
(933, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'may require', 'Combining of these drugs to maximize rescue of DeltaF508 CFTR may require changes in dosing and/or development of new potentiator compounds that do not interfere with CFTR stability .'),
(934, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be in', 'Combining of these drugs to maximize rescue of DeltaF508 CFTR may require changes in dosing and/or development of new potentiator compounds that do not interfere with CFTR stability .'),
(935, 25101886, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'may require', 'Combining of these drugs to maximize rescue of DeltaF508 CFTR may require changes in dosing and/or development of new potentiator compounds that do not interfere with CFTR stability .'),
(936, 25568582, 'MESH:D000535', 'al', 'Chemical', '9606', 'men', 'Species', 'be with', 'Results : There was a significant relationship between organization resource , organizational knowledge , process , management structure and values and goals with implementation of information technology .'),
(937, 25568582, 'MESH:D000535', 'al', 'Chemical', '9606', 'men', 'Species', 'impact on', 'Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .'),
(938, 25568582, 'MESH:D000535', 'al', 'Chemical', '9606', 'men', 'Species', 'impact on', 'Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .'),
(939, 25568582, 'MESH:D000535', 'al', 'Chemical', '9606', 'men', 'Species', 'have', 'Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .'),
(940, 25568582, 'MESH:D000535', 'al', 'Chemical', '9606', 'men', 'Species', 'have', 'Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .'),
(941, 25568582, 'MESH:D000535', 'al', 'Chemical', '9606', 'men', 'Species', 'have', 'Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .'),
(942, 25568582, 'MESH:D000535', 'al', 'Chemical', '9606', 'men', 'Species', 'considerable impact on', 'Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .'),
(943, 25568582, 'MESH:D000535', 'al', 'Chemical', '9606', 'men', 'Species', 'have', 'Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .'),
(944, 25568582, 'MESH:D000535', 'al', 'Chemical', '9606', 'men', 'Species', 'considerable impact on', 'Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .'),
(945, 25481785, 'MESH:D009584', 'n', 'Chemical', '8078', 'killifish', 'Species', 'be in', 'Targeted mutagenesis of aryl hydrocarbon receptor 2a and 2b genes in Atlantic killifish -LRB- Fundulus heteroclitus -RRB- .'),
(946, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'include', 'While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .'),
(947, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'include', 'While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .'),
(948, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'include', 'While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .'),
(949, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'use', 'While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .'),
(950, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'use', 'While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .'),
(951, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'include', 'While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .'),
(952, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'use', 'While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .'),
(953, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'use', 'While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .'),
(954, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'have include', 'While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .'),
(955, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'use', 'While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .'),
(956, 25481785, '8078', 'killifish', 'Species', '30517', 'ahr2', 'Gene', 'in 2a be', 'To facilitate evaluations of toxic mechanisms for important categories of aryl hydrocarbon pollutants , whose actions are known to be receptor mediated , we used ZFN and CRISPR-Cas9 approaches to generate aryl hydrocarbon receptor 2a -LRB- AHR2a -RRB- and AHR2b gene mutations in Atlantic killifish -LRB- Fundulus heteroclitus -RRB- embryos .'),
(957, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'be', 'This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .'),
(958, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'be', 'This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .'),
(959, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'be', 'This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .'),
(960, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'be', 'This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .'),
(961, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'be', 'This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .'),
(962, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'be', 'This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .'),
(963, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'be', 'This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .'),
(964, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'be', 'This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .'),
(965, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'be', 'This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .'),
(966, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'be', 'This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .'),
(967, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'have evolve resistance in', 'In addition , some populations of this species have evolved resistance to toxicants such as halogenated aromatic hydrocarbons .'),
(968, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'have evolve', 'In addition , some populations of this species have evolved resistance to toxicants such as halogenated aromatic hydrocarbons .'),
(969, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'have evolve', 'In addition , some populations of this species have evolved resistance to toxicants such as halogenated aromatic hydrocarbons .'),
(970, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'characterize', 'AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .'),
(971, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'characterize', 'AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .'),
(972, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'characterize', 'AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .'),
(973, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'characterize', 'AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .'),
(974, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'characterize', 'AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .'),
(975, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'characterize', 'AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .'),
(976, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'characterize', 'AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .'),
(977, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'characterize', 'AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .'),
(978, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'characterize', 'AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .'),
(979, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'characterize', 'AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .'),
(980, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'characterize', 'AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .'),
(981, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'characterize', 'AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .'),
(982, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'characterize', 'AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .'),
(983, 25481785, '8078', 'killifish', 'Species', 'MESH:D009584', 'n', 'Chemical', 'characterize', 'AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .'),
(984, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'target', 'Subsequently , CRISPR-Cas9 guide RNAs were designed to target regions in exon 2 and 3 of AHR2a and AHR2b .'),
(985, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Subsequently , CRISPR-Cas9 guide RNAs were designed to target regions in exon 2 and 3 of AHR2a and AHR2b .'),
(986, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'target', 'Subsequently , CRISPR-Cas9 guide RNAs were designed to target regions in exon 2 and 3 of AHR2a and AHR2b .'),
(987, 25481785, 'MESH:D009584', 'n', 'Chemical', '30517', 'ahr2', 'Gene', 'be in', 'Subsequently , CRISPR-Cas9 guide RNAs were designed to target regions in exon 2 and 3 of AHR2a and AHR2b .'),
(988, 25481785, 'MESH:D009584', 'n', 'Chemical', '30517', 'ahr2', 'Gene', 'target', 'Subsequently , CRISPR-Cas9 guide RNAs were designed to target regions in exon 2 and 3 of AHR2a and AHR2b .'),
(989, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Subsequently , CRISPR-Cas9 guide RNAs were designed to target regions in exon 2 and 3 of AHR2a and AHR2b .'),
(990, 25481785, 'MESH:D009584', 'n', 'Chemical', '30517', 'ahr2', 'Gene', 'target', 'Subsequently , CRISPR-Cas9 guide RNAs were designed to target regions in exon 2 and 3 of AHR2a and AHR2b .'),
(991, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be with', 'We successfully induced frameshift mutations in AHR2a exon 3 with ZFN and CRISPR-Cas9 guide RNAs , with mutation frequencies of 10 % and 16 % , respectively .'),
(992, 25481785, 'MESH:D009584', 'n', 'Chemical', '30517', 'ahr2', 'Gene', 'be in', 'We successfully induced frameshift mutations in AHR2a exon 3 with ZFN and CRISPR-Cas9 guide RNAs , with mutation frequencies of 10 % and 16 % , respectively .'),
(993, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'In AHR2b , mutations were induced using CRISPR-Cas9 guide RNAs targeting sites in both exon 2 -LRB- 17 % -RRB- and exon 3 -LRB- 63 % -RRB- .'),
(994, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'target', 'In AHR2b , mutations were induced using CRISPR-Cas9 guide RNAs targeting sites in both exon 2 -LRB- 17 % -RRB- and exon 3 -LRB- 63 % -RRB- .'),
(995, 25481785, 'MESH:D009584', 'n', 'Chemical', '30517', 'ahr2', 'Gene', 'be induce in', 'In AHR2b , mutations were induced using CRISPR-Cas9 guide RNAs targeting sites in both exon 2 -LRB- 17 % -RRB- and exon 3 -LRB- 63 % -RRB- .'),
(996, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'use', 'In AHR2b , mutations were induced using CRISPR-Cas9 guide RNAs targeting sites in both exon 2 -LRB- 17 % -RRB- and exon 3 -LRB- 63 % -RRB- .'),
(997, 25481785, 'MESH:D009584', 'n', 'Chemical', '6239', 'embryo', 'Species', 'induce mutation at', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(998, 25481785, 'MESH:D009584', 'n', 'Chemical', '6239', 'embryo', 'Species', 'induce mutation at', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(999, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1000, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1001, 25481785, 'MESH:D009584', 'n', 'Chemical', '6239', 'embryo', 'Species', 'induce mutation at', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1002, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1003, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1004, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1005, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1006, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1007, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1008, 25481785, 'MESH:D009584', 'n', 'Chemical', '6239', 'embryo', 'Species', 'induce mutation at', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1009, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'induce', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1010, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1011, 25481785, 'MESH:D009584', 'n', 'Chemical', '6239', 'embryo', 'Species', 'induce mutation at', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1012, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1013, 25481785, 'MESH:D009584', 'n', 'Chemical', '6239', 'embryo', 'Species', 'induce mutation at', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1014, 25481785, 'MESH:D009584', 'n', 'Chemical', '6239', 'embryo', 'Species', 'induce mutation at', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1015, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1016, 25481785, 'MESH:D009584', 'n', 'Chemical', '6239', 'embryo', 'Species', 'induce mutation at', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1017, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1018, 25481785, 'MESH:D009584', 'n', 'Chemical', '6239', 'embryo', 'Species', 'induce mutation at', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1019, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1020, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'induce', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1021, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1022, 25481785, 'MESH:D009584', 'n', 'Chemical', '6239', 'embryo', 'Species', 'induce mutation at', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1023, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1024, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1025, 25481785, 'MESH:D009584', 'n', 'Chemical', '6239', 'embryo', 'Species', 'induce mutation at', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1026, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1027, 25481785, 'MESH:D009584', 'n', 'Chemical', '6239', 'embryo', 'Species', 'induce mutation at', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1028, 25481785, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be efficient without', 'Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .'),
(1029, 1618904, 'MESH:D010009', 'chondrodysplasia', 'Disease', '10090', 'mouse', 'Species', 'be in', 'Chondrodysplasia in transgenic mice harboring a 15-amino acid deletion in the triple helical domain of pro alpha 1 -LRB- II -RRB- collagen chain .'),
(1030, 1577865, '9606', 'mammalian', 'Species', '9913', 'bovine', 'Species', 'prepared from', 'We have addressed this question by directly microinjecting mammalian profilins , prepared either from an E. coli expression system or from bovine brain , into living normal rat kidney -LRB- NRK -RRB- cells .'),
(1031, 1560026, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .'),
(1032, 1560026, 'MESH:C007816', 'beta-galactoside', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .'),
(1033, 1560026, 'MESH:C007816', 'beta-galactoside', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .'),
(1034, 1560026, 'MESH:C007816', 'beta-galactoside', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .'),
(1035, 1560026, 'MESH:C007816', 'beta-galactoside', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .'),
(1036, 1560026, 'MESH:C007816', 'beta-galactoside', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .'),
(1037, 1560026, 'MESH:C007816', 'beta-galactoside', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .'),
(1038, 1560026, 'MESH:C007816', 'beta-galactoside', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .'),
(1039, 1560026, 'MESH:C007816', 'beta-galactoside', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .'),
(1040, 1560026, 'MESH:C007816', 'beta-galactoside', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .'),
(1041, 1560026, 'MESH:C007816', 'beta-galactoside', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .'),
(1042, 1560026, 'MESH:C007816', 'beta-galactoside', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .'),
(1043, 1560026, 'MESH:C007816', 'beta-galactoside', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .'),
(1044, 1560026, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'A series of experiments has shown that the 17-residue transmembrane domain of ST is sufficient to confer localization to the Golgi apparatus when transferred to the corresponding region of a cell surface type II integral membrane protein .'),
(1045, 1560026, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'confer', 'A series of experiments has shown that the 17-residue transmembrane domain of ST is sufficient to confer localization to the Golgi apparatus when transferred to the corresponding region of a cell surface type II integral membrane protein .'),
(1046, 1560026, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'confer', 'A series of experiments has shown that the 17-residue transmembrane domain of ST is sufficient to confer localization to the Golgi apparatus when transferred to the corresponding region of a cell surface type II integral membrane protein .'),
(1047, 1560026, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'A series of experiments has shown that the 17-residue transmembrane domain of ST is sufficient to confer localization to the Golgi apparatus when transferred to the corresponding region of a cell surface type II integral membrane protein .'),
(1048, 1560026, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'localized in', 'Lectin affinity chromatography of chimeric proteins bearing this 17-residue sequence suggests that these chimeric proteins are localized in the trans-Golgi cisternae and/or trans-Golgi network .'),
(1049, 1560026, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'localized in', 'Lectin affinity chromatography of chimeric proteins bearing this 17-residue sequence suggests that these chimeric proteins are localized in the trans-Golgi cisternae and/or trans-Golgi network .'),
(1050, 1560026, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'localized in', 'Lectin affinity chromatography of chimeric proteins bearing this 17-residue sequence suggests that these chimeric proteins are localized in the trans-Golgi cisternae and/or trans-Golgi network .'),
(1051, 1560026, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'localized in', 'Lectin affinity chromatography of chimeric proteins bearing this 17-residue sequence suggests that these chimeric proteins are localized in the trans-Golgi cisternae and/or trans-Golgi network .'),
(1052, 1533397, '3799', 'kinesin heavy chain', 'Gene', '3799', 'khc', 'Gene', 'study', 'To examine the function of kinesin in neurons , we sought to suppress kinesin heavy chain -LRB- KHC -RRB- expression in cultured hippocampal neurons using antisense oligonucleotides and study the phenotype of these KHC `` null '''' cells .'),
(1053, 1533397, '3799', 'kinesin heavy chain', 'Gene', '3799', 'khc', 'Gene', 'study', 'To examine the function of kinesin in neurons , we sought to suppress kinesin heavy chain -LRB- KHC -RRB- expression in cultured hippocampal neurons using antisense oligonucleotides and study the phenotype of these KHC `` null '''' cells .'),
(1054, 25530839, '735281', 'mir', 'Gene', 'CVCL:M564', 'es', 'CellLine', 'be', 'The two miR-1 / 133a clusters generate identical mature miR-1 and miR-133a miRNAs in heart and skeletal muscle , while the cognate miR-206 / 133b cluster is exclusively expressed in skeletal muscle .'),
(1055, 25530839, '735281', 'mir', 'Gene', 'CVCL:M564', 'es', 'CellLine', 'be', 'The two miR-1 / 133a clusters generate identical mature miR-1 and miR-133a miRNAs in heart and skeletal muscle , while the cognate miR-206 / 133b cluster is exclusively expressed in skeletal muscle .'),
(1056, 25530839, '735281', 'mir', 'Gene', 'CVCL:M564', 'es', 'CellLine', 'be', 'The two miR-1 / 133a clusters generate identical mature miR-1 and miR-133a miRNAs in heart and skeletal muscle , while the cognate miR-206 / 133b cluster is exclusively expressed in skeletal muscle .'),
(1057, 25530839, '735281', 'mir', 'Gene', 'CVCL:M564', 'es', 'CellLine', 'be', 'The two miR-1 / 133a clusters generate identical mature miR-1 and miR-133a miRNAs in heart and skeletal muscle , while the cognate miR-206 / 133b cluster is exclusively expressed in skeletal muscle .'),
(1058, 25530839, '735281', 'mir', 'Gene', '735281', 'mir', 'Gene', 'contain', 'Similarly , miR-1 and miR-206 are structurally related and contain identical seed sequences important for miRNA-target recognition .'),
(1059, 25530839, '735281', 'mir', 'Gene', '735281', 'mir', 'Gene', 'contain', 'Similarly , miR-1 and miR-206 are structurally related and contain identical seed sequences important for miRNA-target recognition .'),
(1060, 1577858, '10090', 'mouse', 'Species', '9606', 'human', 'Species', 'be transfect with', 'C2 mouse myoblasts were transfected with the human beta - and gamma-actin genes .'),
(1061, 1315319, '81008', 'h36-alpha 7', 'Gene', '24511', 'integrin beta 1', 'Gene', 'be associate with', 'Immunoblots and immunofluorescence demonstrate that the H36-alpha 7 chain is associated with integrin beta 1 .'),
(1062, 25530820, '4292', 'mlh1', 'Gene', 'MESH:D003123', 'lynch syndrome', 'Disease', 'be in', 'Nucleosome positioning is unaltered at MLH1 splice site mutations in cells derived from Lynch syndrome patients .'),
(1063, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D003123', 'lynch syndrome', 'Disease', 'be unaltered at', 'Nucleosome positioning is unaltered at MLH1 splice site mutations in cells derived from Lynch syndrome patients .'),
(1064, 25530820, 'MESH:D002244', 'c', 'Chemical', '4292', 'mlh1', 'Gene', 'be unaltered at', 'Nucleosome positioning is unaltered at MLH1 splice site mutations in cells derived from Lynch syndrome patients .'),
(1065, 25530820, 'MESH:D002244', 'c', 'Chemical', '4292', 'mlh1', 'Gene', 'be unaltered at', 'Nucleosome positioning is unaltered at MLH1 splice site mutations in cells derived from Lynch syndrome patients .'),
(1066, 25530820, 'MESH:D002244', 'c', 'Chemical', '4292', 'mlh1', 'Gene', 'be unaltered at', 'Nucleosome positioning is unaltered at MLH1 splice site mutations in cells derived from Lynch syndrome patients .'),
(1067, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'be important for', 'Background Splicing is more efficient when coupled with transcription and it has been proposed that nucleosomes enriched in exons are important for splice site recognition .'),
(1068, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'couple with', 'Background Splicing is more efficient when coupled with transcription and it has been proposed that nucleosomes enriched in exons are important for splice site recognition .'),
(1069, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'be', 'Background Splicing is more efficient when coupled with transcription and it has been proposed that nucleosomes enriched in exons are important for splice site recognition .'),
(1070, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'be', 'Background Splicing is more efficient when coupled with transcription and it has been proposed that nucleosomes enriched in exons are important for splice site recognition .'),
(1071, 25530820, 'MESH:D003123', 'lynch syndrome', 'Disease', 'MESH:D009369', 'cancer', 'Disease', 'be', 'Lynch syndrome is a familial cancer syndrome that can be caused by the autosomal dominant inheritance of splice site mutations in the MutL homolog 1 -LRB- MLH1 -RRB- gene .'),
(1072, 25530820, 'MESH:D003123', 'lynch syndrome', 'Disease', 'MESH:D009369', 'cancer', 'Disease', 'be', 'Lynch syndrome is a familial cancer syndrome that can be caused by the autosomal dominant inheritance of splice site mutations in the MutL homolog 1 -LRB- MLH1 -RRB- gene .'),
(1073, 25530820, 'MESH:D002244', 'c', 'Chemical', '4292', 'mutl homolog 1', 'Gene', 'be in', 'Lynch syndrome is a familial cancer syndrome that can be caused by the autosomal dominant inheritance of splice site mutations in the MutL homolog 1 -LRB- MLH1 -RRB- gene .'),
(1074, 25530820, '4292', 'mlh1', 'Gene', 'MESH:D003123', 'lynch syndrome', 'Disease', 'be in', 'To better understand the role of nucleosomes in splicing , we used MLH1 splice site mutations in Lynch syndrome cases as a model to investigate if abnormal splicing was associated with altered nucleosome positioning at exon-intron boundaries .'),
(1075, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'allele-specific positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1076, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1077, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D003123', 'lynch syndrome', 'Disease', 'positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1078, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1079, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D003123', 'lynch syndrome', 'Disease', 'positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1080, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1081, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1082, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1083, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1084, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1085, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'allele-specific positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1086, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D003123', 'lynch syndrome', 'Disease', 'positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1087, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D003123', 'lynch syndrome', 'Disease', 'allele-specific positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1088, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D003123', 'lynch syndrome', 'Disease', 'be in', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1089, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D003123', 'lynch syndrome', 'Disease', 'allele-specific positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1090, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'allele-specific positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1091, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'allele-specific positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1092, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'allele-specific positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1093, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'positioning of', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1094, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'allele-specific positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1095, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'allele-specific positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1096, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'allele-specific positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1097, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D003123', 'lynch syndrome', 'Disease', 'allele-specific positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1098, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D003123', 'lynch syndrome', 'Disease', 'positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1099, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'allele-specific positioning of', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1100, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'allele-specific positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1101, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'allele-specific positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1102, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D003123', 'lynch syndrome', 'Disease', 'allele-specific positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1103, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1104, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1105, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'positioning around', 'Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .'),
(1106, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1107, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1108, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1109, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1110, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1111, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1112, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1113, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1114, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1115, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1116, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1117, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1118, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1119, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1120, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1121, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1122, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1123, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1124, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1125, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1126, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1127, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1128, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1129, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'reveal', 'Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .'),
(1130, 25530820, 'MESH:D002244', 'c', 'Chemical', '4292', 'mlh1', 'Gene', 'be', 'Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .'),
(1131, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'be enrich in', 'Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .'),
(1132, 25530820, 'MESH:D002244', 'c', 'Chemical', '4292', 'mlh1', 'Gene', 'be', 'Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .'),
(1133, 25530820, 'MESH:D002244', 'c', 'Chemical', '4292', 'mlh1', 'Gene', 'be enrich at', 'Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .'),
(1134, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'be', 'Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .'),
(1135, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D003123', 'lynch syndrome', 'Disease', 'be enrich in', 'Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .'),
(1136, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D003123', 'lynch syndrome', 'Disease', 'be', 'Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .'),
(1137, 25530820, 'MESH:D002244', 'c', 'Chemical', 'MESH:D002244', 'c', 'Chemical', 'be enrich in', 'Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .'),
(1138, 1607386, '2720', 'beta-galactosidase', 'Gene', 'MESH:D000641', 'nh2', 'Chemical', 'localize phospholipid binding domain in', 'We used bacterially expressed beta-galactosidase fusion proteins to localize the phospholipid binding domain of Acanthamoeba myosin IC to the region between amino acids 701 and 888 in the NH2-terminal half of the tail .'),
(1139, 1607386, '2720', 'beta-galactosidase', 'Gene', '4641', 'myosin ic', 'Gene', 'localize', 'We used bacterially expressed beta-galactosidase fusion proteins to localize the phospholipid binding domain of Acanthamoeba myosin IC to the region between amino acids 701 and 888 in the NH2-terminal half of the tail .'),
(1140, 1607386, '2720', 'beta-galactosidase', 'Gene', 'MESH:D000641', 'nh2', 'Chemical', 'localize phospholipid binding domain in', 'We used bacterially expressed beta-galactosidase fusion proteins to localize the phospholipid binding domain of Acanthamoeba myosin IC to the region between amino acids 701 and 888 in the NH2-terminal half of the tail .'),
(1141, 1607386, 'MESH:D000255', 'atp', 'Chemical', 'MESH:D015823', 'acanthamoeba myosin ia', 'Disease', 'be contain', 'We confirm that the ATP-insensitive actin binding site is contained in the COOH-terminal 30 kD of the tail as previously shown for Acanthamoeba myosin IA .'),
(1142, 1607386, 'MESH:D000255', 'atp', 'Chemical', 'MESH:C102887', 'cooh', 'Chemical', 'be contain in', 'We confirm that the ATP-insensitive actin binding site is contained in the COOH-terminal 30 kD of the tail as previously shown for Acanthamoeba myosin IA .'),
(1143, 1607386, 'MESH:D000255', 'atp', 'Chemical', 'MESH:D015823', 'acanthamoeba myosin ia', 'Disease', 'previously show for', 'We confirm that the ATP-insensitive actin binding site is contained in the COOH-terminal 30 kD of the tail as previously shown for Acanthamoeba myosin IA .'),
(1144, 1607386, 'MESH:D000255', 'atp', 'Chemical', 'MESH:C102887', 'cooh', 'Chemical', 'be contain in', 'We confirm that the ATP-insensitive actin binding site is contained in the COOH-terminal 30 kD of the tail as previously shown for Acanthamoeba myosin IA .'),
(1145, 1607386, 'MESH:D000255', 'atp', 'Chemical', 'MESH:D015823', 'acanthamoeba myosin ia', 'Disease', 'be contain', 'We confirm that the ATP-insensitive actin binding site is contained in the COOH-terminal 30 kD of the tail as previously shown for Acanthamoeba myosin IA .'),
(1146, 1607386, 'MESH:D000255', 'atp', 'Chemical', 'MESH:D015823', 'acanthamoeba myosin ia', 'Disease', 'show for', 'We confirm that the ATP-insensitive actin binding site is contained in the COOH-terminal 30 kD of the tail as previously shown for Acanthamoeba myosin IA .'),
(1147, 1352300, 'MESH:C524118', 'bfa', 'Chemical', 'MESH:D018819', 'dppiv', 'Chemical', 'abolish', 'BFA was found to abolish the apical targeting of DPPIV .'),
(1148, 1352300, 'MESH:C524118', 'bfa', 'Chemical', 'MESH:D018819', 'dppiv', 'Chemical', 'abolish', 'BFA was found to abolish the apical targeting of DPPIV .'),
(1149, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1150, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1151, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be transcytose back after', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1152, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be transcytose back after', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1153, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be transcytose after', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1154, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1155, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be transcytose after', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1156, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1157, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be transcytose after', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1158, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be transcytose back after', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1159, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be transcytose after', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1160, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1161, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be transcytose back after', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1162, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1163, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1164, 1352300, 'MESH:D018819', 'dppiv', 'Chemical', 'MESH:C524118', 'bfa', 'Chemical', 'be', 'The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .'),
(1165, 1374069, '3779', 'beta 1', 'Gene', '2335', 'fibronectin', 'Gene', 'binding to', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1166, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'binding of', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1167, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'binding of', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1168, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'binding of', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1169, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'strongly enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1170, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'strongly enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1171, 1374069, '3779', 'beta 1', 'Gene', '2335', 'fibronectin', 'Gene', 'strongly enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1172, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'strongly enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1173, 1374069, '3779', 'beta 1', 'Gene', '2335', 'fibronectin', 'Gene', 'enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1174, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'binding of', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1175, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'strongly enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1176, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1177, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'strongly enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1178, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1179, 1374069, '3779', 'beta 1', 'Gene', '2335', 'fibronectin', 'Gene', 'binding to', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1180, 1374069, '3779', 'beta 1', 'Gene', '2335', 'fibronectin', 'Gene', 'enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1181, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1182, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1183, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1184, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'strongly enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1185, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1186, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'strongly enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1187, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1188, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1189, 1374069, '3779', 'beta 1', 'Gene', '2335', 'fibronectin', 'Gene', 'strongly enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1190, 1374069, '3779', 'beta 1', 'Gene', 'CVCL:0007', 'u-937', 'CellLine', 'strongly enhance', 'We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .'),
(1191, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'involve', 'This beta 1-mediated regulatory effect involved both VLA-4 and VLA-5 fibronectin receptors .'),
(1192, 1374069, '3779', 'beta 1', 'Gene', '2335', 'fibronectin', 'Gene', 'involve', 'This beta 1-mediated regulatory effect involved both VLA-4 and VLA-5 fibronectin receptors .'),
(1193, 1374069, '3779', 'beta 1', 'Gene', '2335', 'fibronectin', 'Gene', 'involve', 'This beta 1-mediated regulatory effect involved both VLA-4 and VLA-5 fibronectin receptors .'),
(1194, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'involve', 'This beta 1-mediated regulatory effect involved both VLA-4 and VLA-5 fibronectin receptors .'),
(1195, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1196, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1197, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1198, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1199, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1200, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1201, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1202, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1203, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1204, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1205, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1206, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1207, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1208, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1209, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1210, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1211, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1212, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1213, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1214, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1215, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1216, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1217, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1218, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1219, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1220, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1221, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1222, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1223, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1224, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1225, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1226, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1227, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1228, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1229, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1230, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1231, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1232, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1233, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1234, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1235, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1236, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1237, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1238, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1239, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1240, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1241, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1242, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1243, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1244, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1245, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1246, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1247, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1248, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1249, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1250, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1251, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1252, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1253, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1254, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1255, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1256, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1257, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1258, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1259, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1260, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1261, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1262, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1263, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1264, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1265, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1266, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1267, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1268, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1269, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1270, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1271, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1272, 1374069, '3779', 'beta 1', 'Gene', '7412', 'vcam-1', 'Gene', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1273, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1274, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1275, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1276, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1277, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1278, 1374069, '3779', 'beta 1', 'Gene', 'MESH:D039041', 'vla-4', 'Chemical', 'moreover also induce', 'Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .'),
(1279, 1374069, 'MESH:D039041', 'vla-4', 'Chemical', '2335', 'fibronectin', 'Gene', 'be with', 'Non - activated peripheral blood T lymphocytes , unable to mediate VLA-4 interactions with fibronectin or VCAM-1 , acquired the ability to bind these ligands in the presence of anti-beta 1 mAb .'),
(1280, 25568626, '9606', 'patient', 'Species', 'MESH:D011655', 'pulmonary thromboembolism', 'Disease', 'be with', 'Objective : Our objective is to show the number of patients with postoperative pulmonary thromboembolism -LRB- PPTE -RRB- treated in Intensive care unit of Clinic for pulmonary diseases an TB `` Podhrastovi '''' in three-year period : from June 1 , 2011 - June 1 , 2014 and to indicate the importance of various surgical operations in the development of pulmonary thromboembolism -LRB- PTE -RRB- .'),
(1281, 25568626, '9606', 'patient', 'Species', 'MESH:D011655', 'pte', 'Disease', 'be with', 'Material and methods : This is the retrospective study which shows the number of patients with PPTE treated in Intensive care unit of Clinic for pulmonary diseases an TB `` Podhrastovi '''' in three-year period : from 01.06.2011.-01.06 .2014 .'),
(1282, 25568626, '9606', 'patient', 'Species', 'MESH:D004617', 'embolus', 'Disease', 'of cent be', 'It represents the number of these patients , per cent of patients with PPTE of total patients with PTE , age and sex of patients , type of surgery , period expressed in days from surgery to diagnosis of PTE , presence of deep venous thrombosis -LRB- DVT -RRB- of lower extremities , massiveness of PPTE e.g. level of pulmonary artery with embolus .'),
(1283, 25568626, '9606', 'patient', 'Species', 'MESH:D011655', 'pte', 'Disease', 'be with', 'It represents the number of these patients , per cent of patients with PPTE of total patients with PTE , age and sex of patients , type of surgery , period expressed in days from surgery to diagnosis of PTE , presence of deep venous thrombosis -LRB- DVT -RRB- of lower extremities , massiveness of PPTE e.g. level of pulmonary artery with embolus .'),
(1284, 25568626, '9606', 'patient', 'Species', 'MESH:D011655', 'pte', 'Disease', 'be with', 'It represents the number of these patients , per cent of patients with PPTE of total patients with PTE , age and sex of patients , type of surgery , period expressed in days from surgery to diagnosis of PTE , presence of deep venous thrombosis -LRB- DVT -RRB- of lower extremities , massiveness of PPTE e.g. level of pulmonary artery with embolus .'),
(1285, 25568626, '9606', 'patient', 'Species', 'MESH:D011655', 'pte', 'Disease', 'be with', 'Results : In three-year period 232 patients with PTE were treated in Intensive care unit of Clinic `` Podhrastovi '''' .'),
(1286, 25568626, 'MESH:D011655', 'pte', 'Disease', '9606', 'patient', 'Species', 'develop in', 'PPTE developed in 15 patients with abdominal , 11 with urologic , 8 with gynecologic , 15 with orthopedic , 4 with cardiologic , 2 with vascular , 3 with neurosurgical , 1 with glandular and 1 with orl operations .'),
(1287, 25568626, 'MESH:D011655', 'pte', 'Disease', '9606', 'patient', 'Species', 'develop in', 'PPTE developed in 15 patients with abdominal , 11 with urologic , 8 with gynecologic , 15 with orthopedic , 4 with cardiologic , 2 with vascular , 3 with neurosurgical , 1 with glandular and 1 with orl operations .'),
(1288, 25568626, '9606', 'patient', 'Species', 'MESH:D020246', 'dvt', 'Disease', 'have', 'Only two patients had acute DVT after operation -LRB- one man and one woman -RRB- , and five had amnesias of previous DVT or PTE .'),
(1289, 25568626, '9606', 'patient', 'Species', 'MESH:D020246', 'dvt', 'Disease', 'have', 'Only two patients had acute DVT after operation -LRB- one man and one woman -RRB- , and five had amnesias of previous DVT or PTE .'),
(1290, 25568626, '9606', 'patient', 'Species', 'MESH:D020246', 'dvt', 'Disease', 'have', 'Only two patients had acute DVT after operation -LRB- one man and one woman -RRB- , and five had amnesias of previous DVT or PTE .'),
(1291, 25568626, '9606', 'patient', 'Species', 'MESH:D020246', 'dvt', 'Disease', 'have', 'Only two patients had acute DVT after operation -LRB- one man and one woman -RRB- , and five had amnesias of previous DVT or PTE .'),
(1292, 25568626, '9606', 'patient', 'Species', 'MESH:D020246', 'dvt', 'Disease', 'be with', 'There is great significance of anticoagulant prophylaxis before surgery even in patients with no anamnesis of previous DVT or PTE .'),
(1293, 1577860, '3309', 'bip', 'Gene', 'CVCL:0529', 'c2', 'CellLine', 'form complex in', 'BiP forms stable complexes with unassembled subunits of the acetylcholine receptor in transfected COS cells and in C2 muscle cells .'),
(1294, 1577860, '3309', 'bip', 'Gene', 'CVCL:0222', 'cos', 'CellLine', 'form complex in', 'BiP forms stable complexes with unassembled subunits of the acetylcholine receptor in transfected COS cells and in C2 muscle cells .'),
(1295, 1577860, '3309', 'bip', 'Gene', 'MESH:D000109', 'acetylcholine', 'Chemical', 'form complex with', 'BiP forms stable complexes with unassembled subunits of the acetylcholine receptor in transfected COS cells and in C2 muscle cells .'),
(1296, 1577860, '3309', 'bip', 'Gene', 'CVCL:0222', 'cos', 'CellLine', 'form complex in', 'BiP forms stable complexes with unassembled subunits of the acetylcholine receptor in transfected COS cells and in C2 muscle cells .'),
(1297, 1577860, '3309', 'bip', 'Gene', 'MESH:D000109', 'acetylcholine', 'Chemical', 'form complex with', 'BiP forms stable complexes with unassembled subunits of the acetylcholine receptor in transfected COS cells and in C2 muscle cells .'),
(1298, 25568630, '9606', 'patient', 'Species', 'MESH:D007674', 'kidney', 'Disease', 'be with', 'Background and aim : Nutrition is a key factor in the treatment of patients with chronic kidney disease because kidney burden decrease causes uremic reduction and its side effects .'),
(1299, 25568630, 'MESH:D002857', 'cr', 'Chemical', '9606', 'patient', 'Species', 'be in', 'There was a significant difference between the creatinine amount in patients before and after of training -LRB- p < = 0.01 -RRB- but no meaningful difference was observed between the BUN amount before and after of training -LRB- p < = 0.031 -RRB- .'),
(1300, 25568633, '9606', 'men', 'Species', '5414', 'mart', 'Gene', 'be in', 'Methods : This cross-sectional study was conducted on Health Management Musters students -LRB- N = 96 -RRB- in Canakkale Onsekiz Mart University Health Sciences Institute , May-June 2014 .'),
(1301, 25568633, '9606', 'people', 'Species', 'MESH:D003866', 'depression', 'Disease', 'be in', 'In our study group according to GHQ scale 32 people -LRB- 55.2 % -RRB- were in the group at risk of depression .'),
(1302, 25568633, '9606', 'people', 'Species', 'MESH:D003866', 'depression', 'Disease', 'be in', 'In our study group according to GHQ scale 32 people -LRB- 55.2 % -RRB- were in the group at risk of depression .'),
(1303, 25568633, '9606', 'people', 'Species', 'MESH:D003866', 'depression', 'Disease', 'be in', 'In our study group according to GHQ scale 32 people -LRB- 55.2 % -RRB- were in the group at risk of depression .'),
(1304, 25568633, '9606', 'people', 'Species', 'MESH:D003866', 'depression', 'Disease', 'be in', 'In our study group according to GHQ scale 32 people -LRB- 55.2 % -RRB- were in the group at risk of depression .'),
(1305, 1577868, '4684', 'ncam', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1306, 1577868, '83501', 'n-cadherin', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'directly promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1307, 1577868, '83501', 'n-cadherin', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'directly promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1308, 1577868, '4684', 'ncam', 'Gene', 'CVCL:0481', 'pc12', 'CellLine', 'directly promote neurite outgrowth from', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1309, 1577868, '83501', 'n-cadherin', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1310, 1577868, '4684', 'ncam', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1311, 1577868, '83501', 'n-cadherin', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'directly promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1312, 1577868, '83501', 'n-cadherin', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'directly promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1313, 1577868, '83501', 'n-cadherin', 'Gene', 'CVCL:0481', 'pc12', 'CellLine', 'directly promote neurite outgrowth from', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1314, 1577868, '4684', 'ncam', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1315, 1577868, '83501', 'n-cadherin', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1316, 1577868, '4684', 'ncam', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'directly promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1317, 1577868, '4684', 'ncam', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'directly promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1318, 1577868, '4684', 'ncam', 'Gene', 'CVCL:0481', 'pc12', 'CellLine', 'promote neurite outgrowth from', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1319, 1577868, '4684', 'ncam', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1320, 1577868, '83501', 'n-cadherin', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1321, 1577868, '4684', 'ncam', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'directly promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1322, 1577868, '83501', 'n-cadherin', 'Gene', 'CVCL:0481', 'pc12', 'CellLine', 'promote neurite outgrowth from', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1323, 1577868, '83501', 'n-cadherin', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1324, 1577868, '4684', 'ncam', 'Gene', 'MESH:D002118', 'calcium', 'Chemical', 'directly promote neurite outgrowth via', 'NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .'),
(1325, 1560029, 'MESH:D014280', 'tag', 'Chemical', 'MESH:C017251', 'dioleoyl phosphatidylcholine', 'Chemical', 'be sonicate with', 'High stability was achieved only when the TAG were sonicated with both oil body PL -LRB- or dioleoyl phosphatidylcholine -RRB- and oleosins of proportions similar to or higher than those in the native oil bodies .'),
(1326, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', 'MESH:D002244', 'c', 'Chemical', 'be express in', 'The BCL6 gene , which is expressed in certain B - and T-cell human lymphomas , is involved with chromosomal rearrangements and mutations in a number of these neoplasms .'),
(1327, 23910958, '12053', 'bcl6', 'Gene', 'MESH:D002244', 'c', 'Chemical', 'be involve with', 'The BCL6 gene , which is expressed in certain B - and T-cell human lymphomas , is involved with chromosomal rearrangements and mutations in a number of these neoplasms .'),
(1328, 23910958, '12053', 'bcl6', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be involve with', 'The BCL6 gene , which is expressed in certain B - and T-cell human lymphomas , is involved with chromosomal rearrangements and mutations in a number of these neoplasms .'),
(1329, 23910958, '12053', 'bcl6', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'The BCL6 gene , which is expressed in certain B - and T-cell human lymphomas , is involved with chromosomal rearrangements and mutations in a number of these neoplasms .'),
(1330, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', 'MESH:D002244', 'c', 'Chemical', 'be express in', 'The BCL6 gene , which is expressed in certain B - and T-cell human lymphomas , is involved with chromosomal rearrangements and mutations in a number of these neoplasms .'),
(1331, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', '10116', 'rat', 'Species', 'be believe', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1332, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', 'MESH:D009369', 'tumor', 'Disease', 'evolve through', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1333, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', 'MESH:D009369', 'tumor', 'Disease', 'be believe', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1334, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', 'MESH:D009369', 'tumor', 'Disease', 'evolve through', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1335, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', 'MESH:D002244', 'c', 'Chemical', 'evolve through', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1336, 23910958, '10116', 'rat', 'Species', 'MESH:D009369', 'tumor', 'Disease', 'be in', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1337, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', '10116', 'rat', 'Species', 'be believe', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1338, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', '10116', 'rat', 'Species', 'evolve through', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1339, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', '10116', 'rat', 'Species', 'evolve through', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1340, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', 'MESH:D002244', 'c', 'Chemical', 'evolve through', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1341, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', '10116', 'rat', 'Species', 'evolve through', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1342, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', 'MESH:D002244', 'c', 'Chemical', 'be believe', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1343, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', '10116', 'rat', 'Species', 'be believe', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1344, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', '10116', 'rat', 'Species', 'evolve through', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1345, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', 'MESH:D009369', 'tumor', 'Disease', 'be believe', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1346, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', '10116', 'rat', 'Species', 'be believe', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1347, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', 'MESH:D009369', 'tumor', 'Disease', 'be believe', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1348, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', 'MESH:D009369', 'tumor', 'Disease', 'evolve through', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1349, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', 'MESH:D009369', 'tumor', 'Disease', 'evolve through', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1350, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', 'MESH:D009369', 'tumor', 'Disease', 'be believe', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1351, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', 'MESH:D002244', 'c', 'Chemical', 'be believe', 'Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .'),
(1352, 23910958, '31931', 'retroviral', 'Species', '10090', 'mouse', 'Species', 'be in', 'We used retroviral insertional mutagenesis in transgenic mice expressing the human BCL6 transgene in order to identify genes that cooperate with BCL6 during lymphomatous transformation .'),
(1353, 23910958, 'MESH:D008223', 'lymphoma', 'Disease', '31931', 'retroviral', 'Species', 'be in', 'We now report three newly identified cooperating genes : GFI1B , EVI5 , and MYB : that we identified in the lymphomas of retroviral-injected BCL6 transgenic mice -LRB- but not in retroviral-injected non-transgenic controls -RRB- ; mRNA and protein expression of GFI1B and EVI5 were decreased in the murine tumors , whereas MYB mRNA and protein expression were increased or decreased .'),
(1354, 23910958, 'MESH:D009584', 'n', 'Chemical', 'MESH:D008223', 'lymphoma', 'Disease', 'correlate with', 'These findings correlated with protein expression in human lymphomas , both B - and T-cell .'),
(1355, 23910958, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'correlate with', 'These findings correlated with protein expression in human lymphomas , both B - and T-cell .'),
(1356, 23910958, 'MESH:D009584', 'n', 'Chemical', 'MESH:D008223', 'lymphoma', 'Disease', 'be in', 'These findings correlated with protein expression in human lymphomas , both B - and T-cell .'),
(1357, 23910958, 'MESH:D009584', 'n', 'Chemical', 'MESH:D008223', 'lymphoma', 'Disease', 'correlate with', 'These findings correlated with protein expression in human lymphomas , both B - and T-cell .'),
(1358, 23910958, '10116', 'rat', 'Species', 'MESH:D009369', 'neoplasm', 'Disease', 'specific to', 'Improved therapy of lymphomas may necessitate the development of combinations of drugs that target the alterations specific to each neoplasm .'),
(1359, 25568631, '', 'intrauterine', 'Chemical', '9606', 'male', 'Species', 'be in', 'Objective : To exam semen parameters in predicting intrauterine insemination -LRB- IUI -RRB- outcomes in couples with male factor .'),
(1360, 25568631, 'MESH:D007246', 'infertile', 'Disease', '9606', 'male', 'Species', 'be with', 'Conclusions : The initial total progressive sperm count lower than 5 * 106 means the poor outcome of IUI in the infertile couples with male factor .'),
(1361, 25568577, 'MESH:D004617', 'embolization', 'Disease', 'MESH:D007680', 'kidney cancer', 'Disease', 'be procedure for', 'ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .'),
(1362, 25568577, 'MESH:D004617', 'embolization', 'Disease', 'MESH:D007680', 'kidney cancer', 'Disease', 'be standard procedure for', 'ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .'),
(1363, 25568577, 'MESH:D004617', 'embolization', 'Disease', 'MESH:D007680', 'kidney cancer', 'Disease', 'be standard procedure for', 'ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .'),
(1364, 25568577, 'MESH:D004617', 'embolization', 'Disease', 'MESH:D007680', 'kidney cancer', 'Disease', 'be procedure for', 'ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .'),
(1365, 25568577, 'MESH:D004617', 'embolization', 'Disease', 'MESH:D007680', 'kidney cancer', 'Disease', 'be procedure for', 'ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .'),
(1366, 25568577, 'MESH:D004617', 'embolization', 'Disease', 'MESH:D007680', 'kidney cancer', 'Disease', 'be standard procedure for', 'ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .'),
(1367, 25568577, 'MESH:D004617', 'embolization', 'Disease', 'MESH:D007680', 'kidney cancer', 'Disease', 'be standard procedure for', 'ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .'),
(1368, 25568577, 'MESH:D004617', 'embolization', 'Disease', 'MESH:D007680', 'kidney cancer', 'Disease', 'be procedure for', 'ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .'),
(1369, 25568577, '9606', 'patient', 'Species', '9606', 'patient', 'Species', 'be compare with', 'All patients with preoperative embolization were compared with the group of 51 patients from Urology Sarajevo , who underwent nephrectomy without preoperative embolization .'),
(1370, 25568577, '9606', 'patient', 'Species', '9606', 'patient', 'Species', 'be compare with', 'All patients with preoperative embolization were compared with the group of 51 patients from Urology Sarajevo , who underwent nephrectomy without preoperative embolization .'),
(1371, 1374068, 'MESH:C032259', 'sds', 'Chemical', '10090', 'mouse', 'Species', 'be insufficient for', 'We found that 1-D SDS-PAGE is insufficient for definitive NF kinetics in the mouse optic system .'),
(1372, 1374068, 'MESH:C032259', 'sds', 'Chemical', '10090', 'mouse', 'Species', 'be insufficient for', 'We found that 1-D SDS-PAGE is insufficient for definitive NF kinetics in the mouse optic system .'),
(1373, 1374068, 'MESH:C032259', 'sds', 'Chemical', '10090', 'mouse', 'Species', 'be insufficient for', 'We found that 1-D SDS-PAGE is insufficient for definitive NF kinetics in the mouse optic system .'),
(1374, 1374068, 'MESH:C032259', 'sds', 'Chemical', '10090', 'mouse', 'Species', 'be insufficient for', 'We found that 1-D SDS-PAGE is insufficient for definitive NF kinetics in the mouse optic system .'),
(1375, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be in', 'Misfolding and aggregation of newly synthesized proteins in the endoplasmic reticulum .'),
(1376, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Newly synthesized Semliki Forest virus spike glycoproteins E1 and p62 and influenza hemagglutinin were studied in infected and transfected tissue culture cells .'),
(1377, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Newly synthesized Semliki Forest virus spike glycoproteins E1 and p62 and influenza hemagglutinin were studied in infected and transfected tissue culture cells .'),
(1378, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Newly synthesized Semliki Forest virus spike glycoproteins E1 and p62 and influenza hemagglutinin were studied in infected and transfected tissue culture cells .'),
(1379, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Newly synthesized Semliki Forest virus spike glycoproteins E1 and p62 and influenza hemagglutinin were studied in infected and transfected tissue culture cells .'),
(1380, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'aggregate in', 'Misfolded proteins aggregated in less than 1 min after release from polysomes and aberrant interchain disulfide bonds were formed immediately .'),
(1381, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'aggregate in', 'Misfolded proteins aggregated in less than 1 min after release from polysomes and aberrant interchain disulfide bonds were formed immediately .'),
(1382, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'This indicated that the formation of complexes was nonspecific , random , and not restricted to products from single polysomes .'),
(1383, 1315315, '3309', 'bip', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'be', 'BiP was associated noncovalently with the aggregates and with some of the nonaggregated products .'),
(1384, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'poor solubility of', 'We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .'),
(1385, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'poor solubility of', 'We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .'),
(1386, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'reflect', 'We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .'),
(1387, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'poor solubility of', 'We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .'),
(1388, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'reflect', 'We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .'),
(1389, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'reflect', 'We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .'),
(1390, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'reflect', 'We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .'),
(1391, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'reflect', 'We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .'),
(1392, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'solubility of', 'We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .'),
(1393, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'reflect', 'We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .'),
(1394, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'solubility of', 'We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .'),
(1395, 1315315, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'solubility of', 'We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .'),
(1396, 1607387, '14453', 'gas2', 'Gene', '10090', 'mouse', 'Species', 'be conserve during', 'Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .'),
(1397, 1607387, '14453', 'gas2', 'Gene', '10090', 'mouse', 'Species', 'be conserve during', 'Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .'),
(1398, 1607387, '14453', 'gas2', 'Gene', '10090', 'mouse', 'Species', 'be well conserve during', 'Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .'),
(1399, 1607387, '14453', 'gas2', 'Gene', '10090', 'mouse', 'Species', 'be well conserve during', 'Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .'),
(1400, 1607387, '14453', 'gas2', 'Gene', '10090', 'mouse', 'Species', 'be conserve during', 'Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .'),
(1401, 1607387, '14453', 'gas2', 'Gene', '10090', 'mouse', 'Species', 'be well conserve during', 'Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .'),
(1402, 1607387, '14453', 'gas2', 'Gene', '10090', 'mouse', 'Species', 'be well conserve during', 'Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .'),
(1403, 1607387, '14453', 'gas2', 'Gene', '10090', 'mouse', 'Species', 'be conserve during', 'Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .'),
(1404, 1607387, '14453', 'gas2', 'Gene', 'CVCL:0594', 'nih 3t3', 'CellLine', 'be in', 'In none of the analyzed oncogene-transformed NIH 3T3 cell lines was Gas2 expression induced under serum starvation .'),
(1405, 1577869, 'MESH:D004492', 'edta', 'Chemical', 'CVCL:M564', 'ecc', 'CellLine', 'first induce', 'First , low temperature and EDTA induced the dissolution of ECC basement membranes and released approximately 80 % of total laminin from the EHS basement membrane .'),
(1406, 1577869, 'MESH:D004492', 'edta', 'Chemical', 'CVCL:M564', 'ecc', 'CellLine', 'induce', 'First , low temperature and EDTA induced the dissolution of ECC basement membranes and released approximately 80 % of total laminin from the EHS basement membrane .'),
(1407, 1577862, '30194', 'neurolin', 'Gene', '7957', 'goldfish', 'Species', 'glycoprotein on', 'Neurolin , a cell surface glycoprotein on growing retinal axons in the goldfish visual system , is reexpressed during retinal axonal regeneration .'),
(1408, 1577862, 'MESH:D000641', 'nh2', 'Chemical', '9031', 'chicken', 'Species', 'have', 'The NH2-terminal amino acid sequence has homologies to the cell adhesion molecule DM-Grasp recently described in the chicken .'),
(1409, 1577862, 'MESH:D000641', 'nh2', 'Chemical', '9031', 'chicken', 'Species', 'have', 'The NH2-terminal amino acid sequence has homologies to the cell adhesion molecule DM-Grasp recently described in the chicken .'),
(1410, 1577862, 'MESH:D000641', 'nh2', 'Chemical', '9031', 'chicken', 'Species', 'have', 'The NH2-terminal amino acid sequence has homologies to the cell adhesion molecule DM-Grasp recently described in the chicken .'),
(1411, 1577862, 'MESH:D000641', 'nh2', 'Chemical', '9031', 'chicken', 'Species', 'have', 'The NH2-terminal amino acid sequence has homologies to the cell adhesion molecule DM-Grasp recently described in the chicken .'),
(1412, 1533642, '10090', 'mouse', 'Species', '12534', 'cdc2', 'Gene', 'be', 'The mouse FT210 cell line is a temperature-sensitive cdc2 mutant .'),
(1413, 1533642, '10090', 'mouse', 'Species', '12534', 'cdc2', 'Gene', 'be', 'The mouse FT210 cell line is a temperature-sensitive cdc2 mutant .'),
(1414, 1533642, '10090', 'mouse', 'Species', '12534', 'cdc2', 'Gene', 'possess', 'We show that mouse cells possess at least two cdc2 - related gene products which form cell cycle regulated histone H1 kinases and we propose that the murine homolog of yeast p34cdc/CDC28 is essential only during the G2-to-M transition in FT210 cells .'),
(1415, 1577872, '1756', 'dystrophin', 'Gene', '9606', 'mammalian', 'Species', 'colocalize in', 'Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .'),
(1416, 1577872, '1756', 'dystrophin', 'Gene', '9606', 'mammalian', 'Species', 'colocalize in', 'Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .'),
(1417, 1577872, '1756', 'dystrophin', 'Gene', '9606', 'mammalian', 'Species', 'colocalize in', 'Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .'),
(1418, 1577872, '1756', 'dystrophin', 'Gene', '9606', 'mammalian', 'Species', 'colocalize in', 'Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .'),
(1419, 1577872, '1756', 'dystrophin', 'Gene', '9606', 'mammalian', 'Species', 'colocalize in', 'Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .'),
(1420, 1577872, '1756', 'dystrophin', 'Gene', '9606', 'mammalian', 'Species', 'colocalize in', 'Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .'),
(1421, 1577872, '1756', 'dystrophin', 'Gene', '9606', 'mammalian', 'Species', 'colocalize in', 'Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .'),
(1422, 1577872, '1756', 'dystrophin', 'Gene', '9606', 'mammalian', 'Species', 'colocalize in', 'Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .'),
(1423, 25568576, 'MESH:D010146', 'pain', 'Disease', '1800', 'mdp', 'Gene', 'be in', 'Back Pain in Children and Diagnostic Value of 99mTc MDP Bone Scintigraphy .'),
(1424, 25568576, '9606', 'child', 'Species', 'MESH:D010146', 'pain', 'Disease', 'be with', 'ABSTRACT Aim : The aim of our study is to assess the diagnostic value of Technituim-99m-Methyle diphosphonate -LRB- 99mTc-MDP -RRB- Bone scintigraphy in the assessment of children with back pain .'),
(1425, 25568576, '9606', 'child', 'Species', 'MESH:D010146', 'pain', 'Disease', 'complain of', 'Methods : Included in this retrospective study were 68 child referred to us complaining of back pain -LRB- mean age of 13 + 2 -RRB- .'),
(1426, 25568576, '9606', 'child', 'Species', 'MESH:D010146', 'pain', 'Disease', 'complain of', 'Methods : Included in this retrospective study were 68 child referred to us complaining of back pain -LRB- mean age of 13 + 2 -RRB- .'),
(1427, 25568576, 'MESH:D009336', 'necrosis', 'Disease', 'MESH:D060048', 'femoral head epiphysis', 'Disease', 'be in', 'Scans findings were suggestive of spondylolysis -LRB- n = 4 -RRB- ; malignancy including primary tumors and metastases -LRB- n = 3 -RRB- ; infection including osteomyelitis and discitis -LRB- n = 3 -RRB- ; sacroiliitis -LRB- n = 2 -RRB- ; benign tumors -LRB- n = 2 -RRB- ; pseudo fractures in ribs -LRB- n = 1 -RRB- ; necrosis in femoral head epiphysis -LRB- n = 1 -RRB- and nonskeletal-renal retention due to hydronephrosis -LRB- n = 1 -RRB- .'),
(1428, 1607388, '3799', 'kinesin heavy chain', 'Gene', 'CVCL:0229', 'cv-1', 'CellLine', 'show distribution after', 'After transient expression in CV-1 cells , the kinesin heavy chain showed both a diffuse distribution and a filamentous staining pattern that coaligned with microtubules but not vimentin intermediate filaments .'),
(1429, 24548058, 'MESH:D008874', 'midazolam', 'Chemical', 'MESH:D004630', 'ems', 'Disease', 'experience degradation throughout', 'Conclusions Midazolam and diazepam experienced minimal degradation throughout 120 days of EMS deployment in high-heat environments .'),
(1430, 24548058, 'MESH:D003975', 'diazepam', 'Chemical', 'MESH:D004630', 'ems', 'Disease', 'experience degradation throughout', 'Conclusions Midazolam and diazepam experienced minimal degradation throughout 120 days of EMS deployment in high-heat environments .'),
(1431, 24548058, 'MESH:D008874', 'midazolam', 'Chemical', 'MESH:D004630', 'ems', 'Disease', 'experience degradation throughout', 'Conclusions Midazolam and diazepam experienced minimal degradation throughout 120 days of EMS deployment in high-heat environments .'),
(1432, 24548058, 'MESH:D003975', 'diazepam', 'Chemical', 'MESH:D004630', 'ems', 'Disease', 'experience degradation throughout', 'Conclusions Midazolam and diazepam experienced minimal degradation throughout 120 days of EMS deployment in high-heat environments .'),
(1433, 24548058, 'MESH:D003975', 'diazepam', 'Chemical', 'MESH:D004630', 'ems', 'Disease', 'experience degradation throughout', 'Conclusions Midazolam and diazepam experienced minimal degradation throughout 120 days of EMS deployment in high-heat environments .'),
(1434, 24548058, 'MESH:D008874', 'midazolam', 'Chemical', 'MESH:D004630', 'ems', 'Disease', 'experience degradation throughout', 'Conclusions Midazolam and diazepam experienced minimal degradation throughout 120 days of EMS deployment in high-heat environments .'),
(1435, 25439054, 'MESH:D003042', 'cocaine', 'Chemical', 'MESH:D008992', 'monkey', 'Disease', 'be in', 'A generalized matching law analysis of cocaine vs. food choice in rhesus monkeys : Effects of candidate ` agonist-based '' medications on sensitivity to reinforcement .'),
(1436, 25439054, 'MESH:D003042', 'cocaine', 'Chemical', 'MESH:D008992', 'monkey', 'Disease', 'be in', 'Background We have previously demonstrated reductions in cocaine choice produced by either continuous 14-day phendimetrazine and D-amphetamine treatment or removing cocaine availability under a cocaine vs. food choice procedure in rhesus monkeys .'),
(1437, 25439054, 'MESH:D003042', 'cocaine', 'Chemical', 'MESH:D008992', 'monkey', 'Disease', 'be in', 'Results GML models provided an excellent fit of the cocaine choice dose-effect functions in individual monkeys .'),
(1438, 1572892, '4932', 's. cerevisiae', 'Species', 'MESH:C540573', 'nbp', 'Chemical', 'from protein be', 'These proteins are recognized by antibodies raised against a previously identified NLS-binding protein -LRB- NBP -RRB- from the yeast S. cerevisiae .'),
(1439, 1315317, '3576', 'il-8', 'Gene', '9768', 'paf', 'Gene', 'be use in', 'When the anti-IL-8 antiserum was used in combination with a PAF receptor antagonist , neutrophil migration across cytokine-pretreated monolayers of EC was completely prevented .'),
(1440, 1315317, '3576', 'il-8', 'Gene', '9768', 'paf', 'Gene', 'be', 'When the anti-IL-8 antiserum was used in combination with a PAF receptor antagonist , neutrophil migration across cytokine-pretreated monolayers of EC was completely prevented .'),
(1441, 1315317, '9606', 'human', 'Species', '9768', 'paf', 'Gene', 'be', 'Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .'),
(1442, 1315317, '9606', 'human', 'Species', '9768', 'paf', 'Gene', 'be', 'Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .'),
(1443, 1315317, '9606', 'human', 'Species', '9768', 'paf', 'Gene', 'be', 'Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .'),
(1444, 1315317, '9606', 'human', 'Species', '9768', 'paf', 'Gene', 'be', 'Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .'),
(1445, 1315317, '9606', 'human', 'Species', '9768', 'paf', 'Gene', 'be', 'Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .'),
(1446, 1315317, '9606', 'human', 'Species', '9768', 'paf', 'Gene', 'be', 'Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .'),
(1447, 1315317, '9606', 'human', 'Species', '9768', 'paf', 'Gene', 'be', 'Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .'),
(1448, 1315317, '9606', 'human', 'Species', '9768', 'paf', 'Gene', 'be activate by', 'Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .'),
(1449, 1315317, '9606', 'human', 'Species', '9768', 'paf', 'Gene', 'be', 'Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .'),
(1450, 1315317, '9606', 'human', 'Species', '9768', 'paf', 'Gene', 'be', 'Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .'),
(1451, 1315317, '9606', 'human', 'Species', '9768', 'paf', 'Gene', 'be activate by', 'Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .'),
(1452, 1315317, '9606', 'human', 'Species', '9768', 'paf', 'Gene', 'be', 'Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .'),
(1453, 1315317, '9606', 'human', 'Species', '9768', 'paf', 'Gene', 'be', 'Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .'),
(1454, 1315317, '9606', 'human', 'Species', '9768', 'paf', 'Gene', 'be', 'Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .'),
(1455, 1607384, 'MESH:D000266', 'amppnp', 'Chemical', '79784', 'myosin', 'Gene', 'cause', 'In physiologically relevant buffers , AMPPNP binding to myosin caused transition to the soluble 10S myosin conformation due to trapping of nucleotide at the active sites .'),
(1456, 1607384, 'MESH:D000266', 'amppnp', 'Chemical', '79784', 'myosin', 'Gene', 'cause', 'In physiologically relevant buffers , AMPPNP binding to myosin caused transition to the soluble 10S myosin conformation due to trapping of nucleotide at the active sites .'),
(1457, 1607384, 'MESH:D000266', 'amppnp', 'Chemical', '79784', 'myosin', 'Gene', 'cause', 'In physiologically relevant buffers , AMPPNP binding to myosin caused transition to the soluble 10S myosin conformation due to trapping of nucleotide at the active sites .'),
(1458, 1607384, 'MESH:D000266', 'amppnp', 'Chemical', '79784', 'myosin', 'Gene', 'cause', 'In physiologically relevant buffers , AMPPNP binding to myosin caused transition to the soluble 10S myosin conformation due to trapping of nucleotide at the active sites .'),
(1459, 1607384, 'MESH:D000266', 'amppnp', 'Chemical', '79784', 'myosin', 'Gene', 'cause', 'In physiologically relevant buffers , AMPPNP binding to myosin caused transition to the soluble 10S myosin conformation due to trapping of nucleotide at the active sites .'),
(1460, 1607384, 'MESH:D000266', 'amppnp', 'Chemical', '79784', 'myosin', 'Gene', 'cause', 'In physiologically relevant buffers , AMPPNP binding to myosin caused transition to the soluble 10S myosin conformation due to trapping of nucleotide at the active sites .'),
(1461, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'cause rearrangement into', 'Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .'),
(1462, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'cause rearrangement into', 'Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .'),
(1463, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'furthermore cause rearrangement into', 'Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .'),
(1464, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'furthermore cause rearrangement into', 'Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .'),
(1465, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'cause rearrangement into', 'Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .'),
(1466, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'furthermore cause rearrangement into', 'Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .'),
(1467, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'cause rearrangement into', 'Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .'),
(1468, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'furthermore cause rearrangement into', 'Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .'),
(1469, 1607384, '', 'severin', 'Chemical', '79784', 'myosin', 'Gene', 'result in', 'Severin-induced fragmentation of actin in actomyosin fibers resulted in immediate disassembly of myosin thick filaments , demonstrating that actin filaments were indispensable for mediating myosin assembly in the presence of AMPPNP .'),
(1470, 1607384, '', 'severin', 'Chemical', '79784', 'myosin', 'Gene', 'result in', 'Severin-induced fragmentation of actin in actomyosin fibers resulted in immediate disassembly of myosin thick filaments , demonstrating that actin filaments were indispensable for mediating myosin assembly in the presence of AMPPNP .'),
(1471, 1607384, '', 'severin', 'Chemical', '79784', 'myosin', 'Gene', 'be in', 'Severin-induced fragmentation of actin in actomyosin fibers resulted in immediate disassembly of myosin thick filaments , demonstrating that actin filaments were indispensable for mediating myosin assembly in the presence of AMPPNP .'),
(1472, 1607384, '', 'severin', 'Chemical', '79784', 'myosin', 'Gene', 'result in', 'Severin-induced fragmentation of actin in actomyosin fibers resulted in immediate disassembly of myosin thick filaments , demonstrating that actin filaments were indispensable for mediating myosin assembly in the presence of AMPPNP .'),
(1473, 1607384, '', 'severin', 'Chemical', '79784', 'myosin', 'Gene', 'result in', 'Severin-induced fragmentation of actin in actomyosin fibers resulted in immediate disassembly of myosin thick filaments , demonstrating that actin filaments were indispensable for mediating myosin assembly in the presence of AMPPNP .'),
(1474, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'also form after', 'Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .'),
(1475, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'form after', 'Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .'),
(1476, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'also form after', 'Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .'),
(1477, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'also form after', 'Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .'),
(1478, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'also form after', 'Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .'),
(1479, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'form after', 'Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .'),
(1480, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'form after', 'Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .'),
(1481, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'form after', 'Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .'),
(1482, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'be spontaneously form by', 'The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .'),
(1483, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'be form by', 'The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .'),
(1484, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'be form by', 'The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .'),
(1485, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'be spontaneously form by', 'The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .'),
(1486, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'be spontaneously form by', 'The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .'),
(1487, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'be spontaneously form by', 'The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .'),
(1488, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'be form by', 'The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .'),
(1489, 1607384, '79784', 'myosin', 'Gene', '79784', 'myosin', 'Gene', 'be form by', 'The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .'),
(1490, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be valid across', 'A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .'),
(1491, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D010146', 'pain', 'Disease', 'involve in', 'A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .'),
(1492, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be valid across', 'A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .'),
(1493, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be valid across', 'A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .'),
(1494, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D010146', 'pain', 'Disease', 'involve in', 'A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .'),
(1495, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be valid across', 'A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .'),
(1496, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D010146', 'pain', 'Disease', 'be valid across', 'A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .'),
(1497, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D010146', 'pain', 'Disease', 'be valid across', 'A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .'),
(1498, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be in', 'Background A validated and reliable instrument was developed to knowledge , attitudes and behaviours with respect to evidence-based practice -LRB- EBB-KABQ -RRB- in medical trainees but requires further adaptation and validation to be applied across different health professionals .'),
(1499, 25495467, 'MESH:D009584', 'n', 'Chemical', '', 'ebb-kabq', 'Chemical', 'in practice be', 'Background A validated and reliable instrument was developed to knowledge , attitudes and behaviours with respect to evidence-based practice -LRB- EBB-KABQ -RRB- in medical trainees but requires further adaptation and validation to be applied across different health professionals .'),
(1500, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be in', 'Methods A modified 33-item evidence-based practice scale -LRB- EBP-KABQ -RRB- was developed to evaluate EBP perceptions and behaviors in clinicians .'),
(1501, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Scaling properties -LRB- internal consistency , floor/ceiling effects -RRB- and construct validity -LRB- association with EBP activities , comparator constructs -RRB- were examined .'),
(1502, 25495467, 'MESH:D009584', 'n', 'Chemical', '10682', 'ebp', 'Gene', 'be with', 'Scaling properties -LRB- internal consistency , floor/ceiling effects -RRB- and construct validity -LRB- association with EBP activities , comparator constructs -RRB- were examined .'),
(1503, 25495467, 'MESH:D009584', 'n', 'Chemical', '10682', 'ebp', 'Gene', 'assess', 'A confirmatory factor analysis was used to assess the 4-domain structure EBP knowledge , attitudes , behavior , outcomes/decisions -RRB- .'),
(1504, 25495467, 'MESH:D009584', 'n', 'Chemical', '10682', 'ebp', 'Gene', 'assess', 'A confirmatory factor analysis was used to assess the 4-domain structure EBP knowledge , attitudes , behavior , outcomes/decisions -RRB- .'),
(1505, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'assess', 'A confirmatory factor analysis was used to assess the 4-domain structure EBP knowledge , attitudes , behavior , outcomes/decisions -RRB- .'),
(1506, 25495467, 'MESH:D009584', 'n', 'Chemical', '10682', 'ebp', 'Gene', 'assess', 'A confirmatory factor analysis was used to assess the 4-domain structure EBP knowledge , attitudes , behavior , outcomes/decisions -RRB- .'),
(1507, 25495467, 'MESH:D009584', 'n', 'Chemical', '10682', 'ebp', 'Gene', 'assess', 'A confirmatory factor analysis was used to assess the 4-domain structure EBP knowledge , attitudes , behavior , outcomes/decisions -RRB- .'),
(1508, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'assess', 'A confirmatory factor analysis was used to assess the 4-domain structure EBP knowledge , attitudes , behavior , outcomes/decisions -RRB- .'),
(1509, 25495467, '10682', 'ebp-kabq', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'support for', 'Results The EBP-KABQ scale demonstrated high internal consistency -LRB- Cronbach ''s alpha = 0.85 -RRB- , no evident floor/ceiling effects , and support for a priori construct validation hypotheses .'),
(1510, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'support for', 'Results The EBP-KABQ scale demonstrated high internal consistency -LRB- Cronbach ''s alpha = 0.85 -RRB- , no evident floor/ceiling effects , and support for a priori construct validation hypotheses .'),
(1511, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'support for', 'Results The EBP-KABQ scale demonstrated high internal consistency -LRB- Cronbach ''s alpha = 0.85 -RRB- , no evident floor/ceiling effects , and support for a priori construct validation hypotheses .'),
(1512, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'support for', 'Results The EBP-KABQ scale demonstrated high internal consistency -LRB- Cronbach ''s alpha = 0.85 -RRB- , no evident floor/ceiling effects , and support for a priori construct validation hypotheses .'),
(1513, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'support for', 'Results The EBP-KABQ scale demonstrated high internal consistency -LRB- Cronbach ''s alpha = 0.85 -RRB- , no evident floor/ceiling effects , and support for a priori construct validation hypotheses .'),
(1514, 25495467, '10682', 'ebp-kabq', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'demonstrate', 'Conclusions The EBP-KABQ scale demonstrates promising psychometric properties in this sample .'),
(1515, 25495467, '10682', 'ebp-kabq', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'demonstrate', 'Conclusions The EBP-KABQ scale demonstrates promising psychometric properties in this sample .'),
(1516, 25495467, '10682', 'ebp-kabq', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'demonstrate', 'Conclusions The EBP-KABQ scale demonstrates promising psychometric properties in this sample .'),
(1517, 25495467, '10682', 'ebp-kabq', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'demonstrate', 'Conclusions The EBP-KABQ scale demonstrates promising psychometric properties in this sample .'),
(1518, 25495467, '10682', 'ebp-kabq', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'demonstrate', 'Conclusions The EBP-KABQ scale demonstrates promising psychometric properties in this sample .'),
(1519, 25495467, '10682', 'ebp-kabq', 'Gene', 'MESH:D009584', 'n', 'Chemical', 'demonstrate', 'Conclusions The EBP-KABQ scale demonstrates promising psychometric properties in this sample .'),
(1520, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'contain', 'Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12909-014-0263-4 -RRB- contains supplementary material , which is available to authorized users .'),
(1521, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'contain', 'Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12909-014-0263-4 -RRB- contains supplementary material , which is available to authorized users .'),
(1522, 25495467, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'contain', 'Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12909-014-0263-4 -RRB- contains supplementary material , which is available to authorized users .'),
(1523, 1607393, 'MESH:C061194', 'sporozoite', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'bind specifically to', 'Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates .'),
(1524, 1607393, 'MESH:C061194', 'sporozoite', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'bind to', 'Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates .'),
(1525, 1607393, 'MESH:C061194', 'sporozoite', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'bind specifically to', 'Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates .'),
(1526, 1607393, 'MESH:C061194', 'sporozoite', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'bind to', 'Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates .'),
(1527, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'also bind', 'The presence of this homology suggests that sporozoites and CS proteins may also bind sulfated glycoconjugates .'),
(1528, 1607393, 'MESH:C061194', 'sporozoite', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'also bind', 'The presence of this homology suggests that sporozoites and CS proteins may also bind sulfated glycoconjugates .'),
(1529, 1607393, 'MESH:C061194', 'sporozoite', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'bind', 'The presence of this homology suggests that sporozoites and CS proteins may also bind sulfated glycoconjugates .'),
(1530, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'bind', 'The presence of this homology suggests that sporozoites and CS proteins may also bind sulfated glycoconjugates .'),
(1531, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'be examine', 'To test this hypothesis , recombinant P. yoelii CS protein was examined for binding to sulfated glycoconjugate-Sepharoses .'),
(1532, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'be examine', 'To test this hypothesis , recombinant P. yoelii CS protein was examined for binding to sulfated glycoconjugate-Sepharoses .'),
(1533, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'bind to', 'To test this hypothesis , recombinant P. yoelii CS protein was examined for binding to sulfated glycoconjugate-Sepharoses .'),
(1534, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'bind to', 'To test this hypothesis , recombinant P. yoelii CS protein was examined for binding to sulfated glycoconjugate-Sepharoses .'),
(1535, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'bind with', 'CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .'),
(1536, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'also bind with', 'CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .'),
(1537, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'also bind with', 'CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .'),
(1538, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'also bind with', 'CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .'),
(1539, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'also bind with', 'CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .'),
(1540, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'bind with', 'CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .'),
(1541, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'also bind with', 'CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .'),
(1542, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'bind with', 'CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .'),
(1543, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'bind with', 'CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .'),
(1544, 1607393, '', 'cs', 'Chemical', 'MESH:D013431', 'sulfate', 'Chemical', 'bind with', 'CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .'),
(1545, 1607393, '', 'cs', 'Chemical', 'MESH:C007789', 'fucoidan', 'Chemical', 'be inhibit by', 'This possibility is consistent with the observation that CS protein binding to hepatocytes , cells invaded by sporozoites during the primary stage of malaria infection , was inhibited by fucoidan , pentosan polysulfate , and heparin .'),
(1546, 1607393, 'MESH:C061194', 'sporozoite', 'Chemical', 'MESH:D013433', 'sulfatide', 'Chemical', 'bind specifically to', 'P. berghei sporozoites bound specifically to sulfatide -LRB- galactosyl -LSB- 3-sulfate -RSB- beta 1-1ceramide -RRB- , but not to comparable levels of cholesterol-3-sulfate , or several examples of neutral glycosphingolipids , gangliosides , or phospholipids .'),
(1547, 1607393, 'MESH:C061194', 'sporozoite', 'Chemical', 'MESH:D013433', 'sulfatide', 'Chemical', 'bind to', 'P. berghei sporozoites bound specifically to sulfatide -LRB- galactosyl -LSB- 3-sulfate -RSB- beta 1-1ceramide -RRB- , but not to comparable levels of cholesterol-3-sulfate , or several examples of neutral glycosphingolipids , gangliosides , or phospholipids .'),
(1548, 1607393, 'MESH:C061194', 'sporozoite', 'Chemical', '', 'cs', 'Chemical', 'parallel', 'Sporozoite invasion into hepatocytes was inhibited by fucoidan , heparin , and dextran sulfate , paralleling the observed binding of CS protein to the corresponding Sepharose derivatives .'),
(1549, 1607393, 'MESH:C061194', 'sporozoite', 'Chemical', 'MESH:C007789', 'fucoidan', 'Chemical', 'be inhibit by', 'Sporozoite invasion into hepatocytes was inhibited by fucoidan , heparin , and dextran sulfate , paralleling the observed binding of CS protein to the corresponding Sepharose derivatives .'),
(1550, 1607393, 'MESH:C061194', 'sporozoite', 'Chemical', '', 'cs', 'Chemical', 'parallel', 'Sporozoite invasion into hepatocytes was inhibited by fucoidan , heparin , and dextran sulfate , paralleling the observed binding of CS protein to the corresponding Sepharose derivatives .'),
(1551, 1607393, 'MESH:C061194', 'sporozoite', 'Chemical', '', 'cs', 'Chemical', 'parallel', 'Sporozoite invasion into hepatocytes was inhibited by fucoidan , heparin , and dextran sulfate , paralleling the observed binding of CS protein to the corresponding Sepharose derivatives .'),
(1552, 1607393, 'MESH:C061194', 'sporozoite', 'Chemical', '', 'cs', 'Chemical', 'parallel', 'Sporozoite invasion into hepatocytes was inhibited by fucoidan , heparin , and dextran sulfate , paralleling the observed binding of CS protein to the corresponding Sepharose derivatives .'),
(1553, 1607393, 'MESH:C061194', 'sporozoite', 'Chemical', '', 'cs', 'Chemical', 'parallel', 'Sporozoite invasion into hepatocytes was inhibited by fucoidan , heparin , and dextran sulfate , paralleling the observed binding of CS protein to the corresponding Sepharose derivatives .'),
(1554, 1607393, 'MESH:C061194', 'sporozoite', 'Chemical', '', 'cs', 'Chemical', 'parallel', 'Sporozoite invasion into hepatocytes was inhibited by fucoidan , heparin , and dextran sulfate , paralleling the observed binding of CS protein to the corresponding Sepharose derivatives .'),
(1555, 1607393, 'MESH:D007239', 'sporozoite infectivity', 'Disease', 'MESH:D016264', 'dextran sulfate', 'Chemical', 'be significantly inhibit by', 'Sporozoite infectivity in mice was significantly inhibited by dextran sulfate 500,000 and fucoidan .'),
(1556, 1607393, 'MESH:D007239', 'sporozoite infectivity', 'Disease', 'MESH:D016264', 'dextran sulfate', 'Chemical', 'be inhibit by', 'Sporozoite infectivity in mice was significantly inhibited by dextran sulfate 500,000 and fucoidan .'),
(1557, 25568636, '9606', 'child', 'Species', '9606', 'child', 'Species', 'postulate warrant child education of', 'Only high-quality , synergistic relationship triad : parent-child-educator and the modern postulates of preschool child education , warrants successful preschool child education .'),
(1558, 25568636, '9606', 'child', 'Species', '9606', 'child', 'Species', 'postulate warrant child education of', 'Only high-quality , synergistic relationship triad : parent-child-educator and the modern postulates of preschool child education , warrants successful preschool child education .'),
(1559, 25568636, '9606', 'child', 'Species', '9606', 'child', 'Species', 'postulate', 'Only high-quality , synergistic relationship triad : parent-child-educator and the modern postulates of preschool child education , warrants successful preschool child education .'),
(1560, 25568636, '9606', 'child', 'Species', '9606', 'child', 'Species', 'postulate', 'Only high-quality , synergistic relationship triad : parent-child-educator and the modern postulates of preschool child education , warrants successful preschool child education .'),
(1561, 25568636, '9606', 'child', 'Species', '9606', 'child', 'Species', 'postulate', 'Only high-quality , synergistic relationship triad : parent-child-educator and the modern postulates of preschool child education , warrants successful preschool child education .'),
(1562, 25568636, '9606', 'child', 'Species', '9606', 'child', 'Species', 'postulate', 'Only high-quality , synergistic relationship triad : parent-child-educator and the modern postulates of preschool child education , warrants successful preschool child education .'),
(1563, 1607391, 'CVCL:G626', 'n2a', 'CellLine', '428253', 'ncam', 'Gene', 'depend on', 'N2A cell adhesion depended on the amount of NCAM applied to the substratum , was cation independent , and was insensitive to treatment with the cytoskeletal perturbing drugs colchicine and cytochalasin D .'),
(1564, 1607391, 'CVCL:G626', 'n2a', 'CellLine', '428253', 'ncam', 'Gene', 'depend on', 'N2A cell adhesion depended on the amount of NCAM applied to the substratum , was cation independent , and was insensitive to treatment with the cytoskeletal perturbing drugs colchicine and cytochalasin D .'),
(1565, 1607391, 'CVCL:G626', 'n2a', 'CellLine', '428253', 'ncam', 'Gene', 'depend on', 'N2A cell adhesion depended on the amount of NCAM applied to the substratum , was cation independent , and was insensitive to treatment with the cytoskeletal perturbing drugs colchicine and cytochalasin D .'),
(1566, 1607382, '3630', 'insulin', 'Gene', 'MESH:D005947', 'glucose', 'Chemical', 'stimulate', 'Insulin stimulates the movement of two glucose transporter isoforms -LRB- GLUT1 and GLUT4 -RRB- to the plasma membrane -LRB- PM -RRB- in adipocytes .'),
(1567, 1607382, '6517', 'glut4', 'Gene', '3630', 'insulin', 'Gene', 'be increase after', 'Whereas GLUT4 labeling of clathrin lattices was only slightly increased after insulin treatment , labeling of uncoated PM regions was markedly increased with insulin .'),
(1568, 1607382, '6517', 'glut4', 'Gene', '3630', 'insulin', 'Gene', 'be only slightly increase after', 'Whereas GLUT4 labeling of clathrin lattices was only slightly increased after insulin treatment , labeling of uncoated PM regions was markedly increased with insulin .'),
(1569, 1607382, '6517', 'glut4', 'Gene', '3630', 'insulin', 'Gene', 'be slightly increase after', 'Whereas GLUT4 labeling of clathrin lattices was only slightly increased after insulin treatment , labeling of uncoated PM regions was markedly increased with insulin .'),
(1570, 1607382, '6517', 'glut4', 'Gene', '3630', 'insulin', 'Gene', 'recycle in', 'These data suggest that GLUT4 recycles from the cell surface both in the presence and absence of insulin .'),
(1571, 1607382, 'MESH:D016244', 'gtp gamma s', 'Chemical', '3630', 'insulin', 'Gene', 'increase pm level', 'In streptolysin-O permeabilized adipocytes , insulin , and GTP gamma S increased PM levels of GLUT4 to a similar extent as observed with insulin in intact cells .'),
(1572, 1607382, 'MESH:D016244', 'gtp gamma s', 'Chemical', '3630', 'insulin', 'Gene', 'increase pm level', 'In streptolysin-O permeabilized adipocytes , insulin , and GTP gamma S increased PM levels of GLUT4 to a similar extent as observed with insulin in intact cells .'),
(1573, 1607382, 'MESH:D016244', 'gtp gamma s', 'Chemical', '6517', 'glut4', 'Gene', 'increase', 'In streptolysin-O permeabilized adipocytes , insulin , and GTP gamma S increased PM levels of GLUT4 to a similar extent as observed with insulin in intact cells .'),
(1574, 1607382, 'MESH:D016244', 'gtp gamma s', 'Chemical', '3630', 'insulin', 'Gene', 'observe with', 'In streptolysin-O permeabilized adipocytes , insulin , and GTP gamma S increased PM levels of GLUT4 to a similar extent as observed with insulin in intact cells .'),
(1575, 1607382, 'MESH:D016244', 'gtp gamma s', 'Chemical', '3630', 'insulin', 'Gene', 'increase pm level', 'In streptolysin-O permeabilized adipocytes , insulin , and GTP gamma S increased PM levels of GLUT4 to a similar extent as observed with insulin in intact cells .'),
(1576, 1607382, '6517', 'glut4', 'Gene', 'MESH:D000255', 'atp', 'Chemical', 'be', 'When insulin and GTP gamma S were added together , in the presence of ATP , PM GLUT4 levels were similar to levels observed when either insulin or GTP gamma S was added individually .'),
(1577, 1607382, '6517', 'glut4', 'Gene', 'MESH:D000255', 'atp', 'Chemical', 'be', 'When insulin and GTP gamma S were added together , in the presence of ATP , PM GLUT4 levels were similar to levels observed when either insulin or GTP gamma S was added individually .'),
(1578, 1607382, '6517', 'glut4', 'Gene', 'MESH:D000255', 'atp', 'Chemical', 'be similar in', 'When insulin and GTP gamma S were added together , in the presence of ATP , PM GLUT4 levels were similar to levels observed when either insulin or GTP gamma S was added individually .'),
(1579, 1607382, '3630', 'insulin', 'Gene', '3630', 'insulin', 'Gene', 'require atp in', 'We conclude that the insulin-stimulated movement of GLUT4 to the cell surface in adipocytes may require ATP early in the insulin signaling pathway and a GTP-binding protein -LRB- s -RRB- at a later step -LRB- s -RRB- .'),
(1580, 1607382, '3630', 'insulin', 'Gene', 'MESH:D000255', 'atp', 'Chemical', 'require', 'We conclude that the insulin-stimulated movement of GLUT4 to the cell surface in adipocytes may require ATP early in the insulin signaling pathway and a GTP-binding protein -LRB- s -RRB- at a later step -LRB- s -RRB- .'),
(1581, 1607382, 'MESH:D000255', 'atp', 'Chemical', '6517', 'glut4', 'Gene', 'insulin-stimulated movement of', 'We conclude that the insulin-stimulated movement of GLUT4 to the cell surface in adipocytes may require ATP early in the insulin signaling pathway and a GTP-binding protein -LRB- s -RRB- at a later step -LRB- s -RRB- .'),
(1582, 1607382, 'MESH:D000255', 'atp', 'Chemical', '6517', 'glut4', 'Gene', 'movement of', 'We conclude that the insulin-stimulated movement of GLUT4 to the cell surface in adipocytes may require ATP early in the insulin signaling pathway and a GTP-binding protein -LRB- s -RRB- at a later step -LRB- s -RRB- .'),
(1583, 1607382, '3630', 'insulin', 'Gene', '3630', 'insulin', 'Gene', 'require atp in', 'We conclude that the insulin-stimulated movement of GLUT4 to the cell surface in adipocytes may require ATP early in the insulin signaling pathway and a GTP-binding protein -LRB- s -RRB- at a later step -LRB- s -RRB- .'),
(1584, 25568628, 'MESH:D012211', 're', 'Chemical', 'MESH:D012211', 're', 'Chemical', 'be in', 'Conclusion : According to the results , we can see that the socioeconomic status of patients had an effect on the occurrence of dental caries and oral hygiene in patients in relation to the rural and urban areas , because we can see that by the number of respondents , the greater unemployment of parents in both , rural and urban areas , caused a host of other factors , which were , either , directly or indirectly connected with the development of caries .'),
(1585, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D010300', 'pd', 'Disease', '''s disease be', 'Parkinson ''s disease -LRB- PD -RRB- is not only characterized by motor disturbances but also , by cognitive , sensory , psychiatric and autonomic dysfunction .'),
(1586, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .'),
(1587, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .'),
(1588, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .'),
(1589, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .'),
(1590, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .'),
(1591, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .'),
(1592, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .'),
(1593, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be in', 'However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .'),
(1594, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .'),
(1595, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be in', 'However , new models are required that reflect the widespread and progressive formation of alpha-syn aggregates in different brain areas .'),
(1596, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Such alpha-syn aggregation is induced in only a few animal models , for example perikaryon inclusions are found in rats administered rotenone , aggregates with a neuritic morphology develop in mice overexpressing either mutated or wild-type alpha-syn , and in Smad3 deficient mice , aggregates form extensively in the perikaryon and neurites of specific brain nuclei .'),
(1597, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Such alpha-syn aggregation is induced in only a few animal models , for example perikaryon inclusions are found in rats administered rotenone , aggregates with a neuritic morphology develop in mice overexpressing either mutated or wild-type alpha-syn , and in Smad3 deficient mice , aggregates form extensively in the perikaryon and neurites of specific brain nuclei .'),
(1598, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Such alpha-syn aggregation is induced in only a few animal models , for example perikaryon inclusions are found in rats administered rotenone , aggregates with a neuritic morphology develop in mice overexpressing either mutated or wild-type alpha-syn , and in Smad3 deficient mice , aggregates form extensively in the perikaryon and neurites of specific brain nuclei .'),
(1599, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be', 'Such alpha-syn aggregation is induced in only a few animal models , for example perikaryon inclusions are found in rats administered rotenone , aggregates with a neuritic morphology develop in mice overexpressing either mutated or wild-type alpha-syn , and in Smad3 deficient mice , aggregates form extensively in the perikaryon and neurites of specific brain nuclei .'),
(1600, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be in', 'In this review we focus on alpha-syn aggregation in the human disorder , its genetics and the availability of experimental models .'),
(1601, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'suggest', 'Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .'),
(1602, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'suggest', 'Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .'),
(1603, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'suggest', 'Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .'),
(1604, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'suggest', 'Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .'),
(1605, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'suggest', 'Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .'),
(1606, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'suggest', 'Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .'),
(1607, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'suggest', 'Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .'),
(1608, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'suggest', 'Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .'),
(1609, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'suggest', 'Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .'),
(1610, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'suggest', 'Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .'),
(1611, 25497491, 'MESH:D009584', 'n', 'Chemical', 'MESH:D009584', 'n', 'Chemical', 'be relate to', 'Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .'),
(1612, 1318884, '14613', 'cx40', 'Gene', '10090', 'mouse', 'Species', 'be', 'The highest overall homology detected , however , was to chick Cx42 -LRB- 67 % amino acid and 86 % nucleotide identity -RRB- , raising the possibility that Cx40 may be the mouse analogue .'),
(1613, 25568624, 'MESH:D000753', 'ra', 'Disease', 'MESH:D009190', 'myelodysplastic syndromes', 'Disease', 'be in', 'Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes .'),
(1614, 25568624, 'MESH:D000753', 'ra', 'Disease', 'MESH:D009190', 'mds', 'Disease', 'can refine prediction in', 'Age , gender , peripheral blood cytopenia , proportion of bone marrow -LRB- BM -RRB- blasts , performance status , comorbidities , transfusion dependence , specific karyotype abnormalities and molecular biomarkers can refine the prediction of prognosis in MDS .'),
(1615, 25568624, 'MESH:D006402', 'cytopenia', 'Disease', 'MESH:D009190', 'mds', 'Disease', 'can refine prediction in', 'Age , gender , peripheral blood cytopenia , proportion of bone marrow -LRB- BM -RRB- blasts , performance status , comorbidities , transfusion dependence , specific karyotype abnormalities and molecular biomarkers can refine the prediction of prognosis in MDS .'),
(1616, 25568624, 'MESH:D000753', 'ra', 'Disease', 'MESH:D009190', 'mds', 'Disease', 'can refine prediction in', 'Age , gender , peripheral blood cytopenia , proportion of bone marrow -LRB- BM -RRB- blasts , performance status , comorbidities , transfusion dependence , specific karyotype abnormalities and molecular biomarkers can refine the prediction of prognosis in MDS .'),
(1617, 25568624, '9606', 'man', 'Species', 'MESH:D009190', 'mds', 'Disease', 'can refine prediction in', 'Age , gender , peripheral blood cytopenia , proportion of bone marrow -LRB- BM -RRB- blasts , performance status , comorbidities , transfusion dependence , specific karyotype abnormalities and molecular biomarkers can refine the prediction of prognosis in MDS .'),
(1618, 25568583, '9606', 'patient', 'Species', 'MESH:C077381', 'varicose', 'Chemical', 'be with', 'It was carried out at Clinic for vascular surgery in Sarajevo where fifty-eight -LRB- 58 -RRB- patients received surgical treatment for varicose veins and in Aesthetic Surgery Center `` Nasa mala klinika '''' in Sarajevo were sixty-one -LRB- 61 -RRB- patients with varicose veins were treated by endovenous laser ablation .'),
(1619, 25568583, 'MESH:D010146', 'pain', 'Disease', '9606', 'patient', 'Species', 'be', 'T test was used for comparing Mean value of visual pain analog scale for the first 7 days between groups , for all seven days pain was significantly higher in surgical group of patients as compared to EVLA group ; p < 0,05 .'),
(1620, 25568583, 'MESH:D010146', 'pain', 'Disease', '9606', 'patient', 'Species', 'be', 'T test was used for comparing Mean value of visual pain analog scale for the first 7 days between groups , for all seven days pain was significantly higher in surgical group of patients as compared to EVLA group ; p < 0,05 .'),
(1621, 25568583, 'MESH:D010146', 'pain', 'Disease', '9606', 'patient', 'Species', 'be', 'T test was used for comparing Mean value of visual pain analog scale for the first 7 days between groups , for all seven days pain was significantly higher in surgical group of patients as compared to EVLA group ; p < 0,05 .'),
(1622, 25568583, 'MESH:D010146', 'pain', 'Disease', '', 'evla', 'Chemical', 'compare to', 'T test was used for comparing Mean value of visual pain analog scale for the first 7 days between groups , for all seven days pain was significantly higher in surgical group of patients as compared to EVLA group ; p < 0,05 .'),
(1623, 25568583, 'MESH:D010146', 'pain', 'Disease', '9606', 'patient', 'Species', 'be', 'T test was used for comparing Mean value of visual pain analog scale for the first 7 days between groups , for all seven days pain was significantly higher in surgical group of patients as compared to EVLA group ; p < 0,05 .'),
(1624, 25568583, '', 'evla', 'Chemical', '9606', 'patient', 'Species', 'offer', 'Conclusion : EVLA offers better patient recovery in terms of significantly lower post treatment pain , faster return to everyday activities and lower incidence of bruising -LRB- hematomas -RRB- .'),
(1625, 25568583, '', 'evla', 'Chemical', 'MESH:D010146', 'pain', 'Disease', 'offer patient recovery in', 'Conclusion : EVLA offers better patient recovery in terms of significantly lower post treatment pain , faster return to everyday activities and lower incidence of bruising -LRB- hematomas -RRB- .'),
(1626, 25568583, '', 'evla', 'Chemical', '9606', 'patient', 'Species', 'offer', 'Conclusion : EVLA offers better patient recovery in terms of significantly lower post treatment pain , faster return to everyday activities and lower incidence of bruising -LRB- hematomas -RRB- .'),
(1627, 25568583, '', 'evla', 'Chemical', 'MESH:D010146', 'pain', 'Disease', 'offer patient recovery in', 'Conclusion : EVLA offers better patient recovery in terms of significantly lower post treatment pain , faster return to everyday activities and lower incidence of bruising -LRB- hematomas -RRB- .'),
(1628, 25568583, '', 'evla', 'Chemical', 'MESH:D010146', 'pain', 'Disease', 'offer patient recovery in', 'Conclusion : EVLA offers better patient recovery in terms of significantly lower post treatment pain , faster return to everyday activities and lower incidence of bruising -LRB- hematomas -RRB- .');